CHEBI ONTOLOGY - ANNOTATIONS |
|
The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
|
Term: | EC 1.14.18.* (oxidoreductase acting on paired donors, miscellaneous compound as one donor, incorporating 1 atom of oxygen) inhibitor |
|
Accession: | CHEBI:76845
|
browse the term
|
Definition: | An EC 1.14.* (oxidoreductase acting on paired donors, with incorporation or reduction of molecular oxygen) inhibitor that interferes with the action of any such enzyme using a miscellaneous compound as one donor and incorporating one atom of oxygen (EC 1.14.18.*). |
Synonyms: | related_synonym: | EC 1.14.18.* inhibitor; EC 1.14.18.* inhibitors; oxidoreductase acting on paired donors, miscellaneous compound as one donor, incorporating 1 atom of oxygen (EC 1.14.18.*) inhibitors |
|
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression |
ISO |
brazilein results in decreased expression of CCND1 mRNA; brazilein results in decreased expression of CCND1 protein |
CTD |
PMID:23948132 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ctnnb1 |
catenin beta 1 |
decreases expression |
ISO |
brazilein results in decreased expression of CTNNB1 protein |
CTD |
PMID:23948132 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
decreases expression |
ISO |
brazilein results in decreased expression of GSK3B protein modified form |
CTD |
PMID:23948132 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions decreases expression |
ISO |
brazilein promotes the reaction [SB 203580 results in decreased expression of and results in decreased activity of MMP2 protein]; brazilein promotes the reaction [wortmannin results in decreased expression of and results in decreased activity of MMP2 protein]; brazilein results in decreased expression of and results in decreased activity of MMP2 protein; SB 203580 promotes the reaction [brazilein results in decreased expression of and results in decreased activity of MMP2 protein]; wortmannin promotes the reaction [brazilein results in decreased expression of and results in decreased activity of MMP2 protein] brazilein results in decreased expression of MMP2 mRNA |
CTD |
PMID:23707804 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
brazilein results in decreased expression of and results in decreased phosphorylation of NFKBIA protein |
CTD |
PMID:23707804 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
decreases expression |
ISO |
brazilein results in decreased expression of RELA protein |
CTD |
PMID:23707804 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
|
G |
Aif1 |
allograft inflammatory factor 1 |
multiple interactions |
ISO |
corilagin inhibits the reaction [Morphine results in increased expression of AIF1 protein]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of AIF1 protein]]; Tunicamycin inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of AIF1 protein]] |
CTD |
PMID:37394652 |
|
NCBI chr20:3,646,784...3,652,670
Ensembl chr20:3,646,777...3,652,668
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions decreases expression |
EXP ISO |
corilagin inhibits the reaction [Doxorubicin results in increased expression of AKT1 protein]; corilagin inhibits the reaction [Methylnitronitrosoguanidine results in increased expression of AKT1 mRNA] corilagin results in decreased expression of AKT1 protein |
CTD |
PMID:34369273 PMID:34605098 PMID:35084093 PMID:35103375 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Atf4 |
activating transcription factor 4 |
multiple interactions |
ISO |
corilagin inhibits the reaction [Morphine results in increased expression of ATF4 protein]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of ATF4 protein]] |
CTD |
PMID:37394652 |
|
NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
EXP |
corilagin inhibits the reaction [Doxorubicin results in increased expression of BAX protein]; corilagin inhibits the reaction [Methylnitronitrosoguanidine results in decreased expression of BAX protein] |
CTD |
PMID:34605098 PMID:35103375 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
EXP |
corilagin inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein]; corilagin inhibits the reaction [Methylnitronitrosoguanidine results in increased expression of BCL2 protein] |
CTD |
PMID:34605098 PMID:35103375 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bsg |
basigin |
multiple interactions |
EXP |
corilagin inhibits the reaction [Methylnitronitrosoguanidine results in increased expression of BSG mRNA] |
CTD |
PMID:35103375 |
|
NCBI chr 7:9,993,170...10,000,387
Ensembl chr 7:9,993,170...10,000,387
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
EXP ISO |
corilagin inhibits the reaction [Doxorubicin results in increased expression of CASP3 protein]; corilagin inhibits the reaction [Methylnitronitrosoguanidine results in decreased expression of CASP3 protein] corilagin inhibits the reaction [Morphine results in increased cleavage of CASP3 protein]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased cleavage of CASP3 protein]]; Tunicamycin inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased cleavage of CASP3 protein]] |
CTD |
PMID:34605098 PMID:35103375 PMID:37394652 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
EXP |
corilagin inhibits the reaction [Methylnitronitrosoguanidine results in decreased expression of CASP9 protein] |
CTD |
PMID:35103375 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions |
EXP ISO |
corilagin inhibits the reaction [Doxorubicin results in decreased activity of CAT protein]; corilagin inhibits the reaction [Methylnitronitrosoguanidine results in decreased activity of CAT protein]; corilagin inhibits the reaction [Streptozocin results in decreased activity of CAT protein] corilagin inhibits the reaction [TNFSF11 protein results in decreased expression of CAT mRNA] |
CTD |
PMID:30582900 PMID:34605098 PMID:35103375 PMID:35307913 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions |
ISO |
corilagin inhibits the reaction [Morphine results in increased expression of DDIT3 protein]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of DDIT3 protein]] |
CTD |
PMID:37394652 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
multiple interactions |
ISO |
corilagin inhibits the reaction [Morphine results in increased phosphorylation of EIF2AK3 protein]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased phosphorylation of EIF2AK3 protein]] |
CTD |
PMID:37394652 |
|
NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911
|
|
G |
Fabp3 |
fatty acid binding protein 3 |
multiple interactions |
EXP |
corilagin inhibits the reaction [Doxorubicin results in increased expression of FABP3 protein] |
CTD |
PMID:34369273 |
|
NCBI chr 5:142,651,962...142,658,707
Ensembl chr 5:142,651,956...142,658,718
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
corilagin inhibits the reaction [TNFSF11 protein results in increased expression of FOS mRNA]; corilagin inhibits the reaction [TNFSF11 protein results in increased expression of FOS protein] |
CTD |
PMID:35307913 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
ISO |
[corilagin co-treated with TNFSF11 protein] results in increased expression of GSR mRNA |
CTD |
PMID:35307913 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions |
EXP |
corilagin inhibits the reaction [Methylnitronitrosoguanidine results in increased expression of HIF1A mRNA] |
CTD |
PMID:35103375 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hmgb1 |
high mobility group box 1 |
multiple interactions |
EXP |
corilagin inhibits the reaction [Methylnitronitrosoguanidine results in increased expression of HMGB1 mRNA] |
CTD |
PMID:35103375 |
|
NCBI chr12:5,972,950...5,979,658
Ensembl chr12:5,901,586...5,978,565 Ensembl chr16:5,901,586...5,978,565
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
multiple interactions |
EXP |
corilagin inhibits the reaction [Doxorubicin results in increased activity of HMGCR protein] |
CTD |
PMID:34605098 |
|
NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
ISO |
corilagin inhibits the reaction [TNFSF11 protein results in decreased expression of HMOX1 protein]; tin protoporphyrin IX inhibits the reaction [corilagin inhibits the reaction [TNFSF11 protein results in decreased expression of HMOX1 protein]] |
CTD |
PMID:35307913 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions |
ISO |
corilagin inhibits the reaction [Morphine results in increased expression of HSPA5 protein]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of HSPA5 protein]] |
CTD |
PMID:37394652 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
corilagin inhibits the reaction [Morphine results in increased expression of IL1B protein]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of IL1B protein]]; Tunicamycin inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of IL1B protein]] |
CTD |
PMID:37394652 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions decreases expression |
EXP ISO |
corilagin inhibits the reaction [Doxorubicin results in increased expression of IL6 protein] corilagin inhibits the reaction [Morphine results in increased expression of IL6 protein]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of IL6 protein]]; Tunicamycin inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of IL6 protein]] corilagin results in decreased expression of IL6 protein |
CTD |
PMID:34369273 PMID:34605098 PMID:35084093 PMID:37394652 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ins1 |
insulin 1 |
multiple interactions |
EXP |
corilagin inhibits the reaction [Streptozocin results in increased secretion of INS1 protein] |
CTD |
PMID:30582900 |
|
NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536
|
|
G |
Ldha |
lactate dehydrogenase A |
multiple interactions |
EXP |
corilagin inhibits the reaction [Methylnitronitrosoguanidine results in increased expression of LDHA mRNA] |
CTD |
PMID:35103375 |
|
NCBI chr 1:97,371,823...97,381,247
Ensembl chr 1:97,366,021...97,433,472
|
|
G |
Mb |
myoglobin |
multiple interactions |
EXP |
corilagin inhibits the reaction [Doxorubicin results in increased expression of MB protein] |
CTD |
PMID:34369273 |
|
NCBI chr 7:108,759,903...108,767,134
Ensembl chr 7:108,759,904...108,767,383
|
|
G |
Nfatc1 |
nuclear factor of activated T-cells 1 |
multiple interactions |
ISO |
corilagin inhibits the reaction [TNFSF11 protein results in increased expression of NFATC1 mRNA]; corilagin inhibits the reaction [TNFSF11 protein results in increased expression of NFATC1 protein] |
CTD |
PMID:35307913 |
|
NCBI chr18:74,046,422...74,156,041
Ensembl chr18:74,046,904...74,156,028
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
ISO |
corilagin inhibits the reaction [TNFSF11 protein results in decreased expression of NFE2L2 mRNA] |
CTD |
PMID:35307913 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
decreases expression |
ISO |
corilagin results in decreased expression of NFKB1 protein |
CTD |
PMID:35084093 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nlrp3 |
NLR family, pyrin domain containing 3 |
multiple interactions |
ISO |
corilagin inhibits the reaction [Morphine results in increased expression of NLRP3 protein]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of NLRP3 protein]]; Tunicamycin inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of NLRP3 protein]] |
CTD |
PMID:37394652 |
|
NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811
|
|
G |
Nos2 |
nitric oxide synthase 2 |
decreases expression multiple interactions |
ISO |
corilagin results in decreased expression of NOS2 protein corilagin inhibits the reaction [Morphine results in increased expression of NOS2 protein]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of NOS2 protein]]; Tunicamycin inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of NOS2 protein]] |
CTD |
PMID:35084093 PMID:37394652 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nppb |
natriuretic peptide B |
multiple interactions |
EXP |
corilagin inhibits the reaction [Doxorubicin results in increased expression of NPPB protein] |
CTD |
PMID:34369273 |
|
NCBI chr 5:158,416,813...158,418,175
Ensembl chr 5:158,416,866...158,418,168
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
multiple interactions |
EXP |
corilagin inhibits the reaction [1-naphthyl isothiocyanate decreases expression of nr1h4 mRNA and protein in rat liver]; corilagin increases expression of nr1h4 mRNA and protein in rat embryonic liver cells |
RGD |
PMID:29235094 |
RGD:15042872 |
NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047
|
|
G |
Pik3cg |
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit gamma |
multiple interactions |
EXP |
corilagin inhibits the reaction [Methylnitronitrosoguanidine results in increased expression of PIK3CG mRNA] |
CTD |
PMID:35103375 |
|
NCBI chr 6:48,766,778...48,802,098
Ensembl chr 6:48,766,864...48,802,043
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
EXP |
corilagin inhibits the reaction [Doxorubicin results in increased expression of PPARG protein] |
CTD |
PMID:34605098 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
decreases expression multiple interactions |
ISO |
corilagin results in decreased expression of PTGS2 protein corilagin inhibits the reaction [Morphine results in increased expression of PTGS2 protein]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of PTGS2 protein]]; Tunicamycin inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of PTGS2 protein]] |
CTD |
PMID:35084093 PMID:37394652 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Pycard |
PYD and CARD domain containing |
multiple interactions |
ISO |
corilagin inhibits the reaction [Morphine results in increased expression of PYCARD protein]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of PYCARD protein]]; Tunicamycin inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of PYCARD protein]] |
CTD |
PMID:37394652 |
|
NCBI chr 1:182,601,657...182,603,013
Ensembl chr 1:182,601,174...182,602,955
|
|
G |
Slc16a3 |
solute carrier family 16 member 3 |
multiple interactions |
EXP |
corilagin inhibits the reaction [Methylnitronitrosoguanidine results in increased expression of SLC16A3 mRNA] |
CTD |
PMID:35103375 |
|
NCBI chr10:106,212,679...106,222,564
Ensembl chr10:106,212,778...106,222,562
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
EXP |
corilagin inhibits the reaction [Doxorubicin results in increased expression of TGFB1 protein] |
CTD |
PMID:34369273 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tlr2 |
toll-like receptor 2 |
multiple interactions |
ISO |
corilagin inhibits the reaction [Morphine results in increased expression of TLR2 mRNA]; corilagin inhibits the reaction [Morphine results in increased expression of TLR2 protein]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased cleavage of CASP3 protein]]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of AIF1 protein]]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of ATF4 protein]]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of DDIT3 protein]]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of HSPA5 protein]]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of IL1B protein]]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of IL6 protein]]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of NLRP3 protein]]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of NOS2 protein]]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of PTGS2 protein]]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of PYCARD protein]]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of TNF protein]]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased phosphorylation of EIF2AK3 protein]] |
CTD |
PMID:37394652 |
|
NCBI chr 2:169,200,620...169,206,819
Ensembl chr 2:169,197,419...169,206,630
|
|
G |
Tnf |
tumor necrosis factor |
decreases secretion multiple interactions decreases expression |
ISO EXP |
corilagin results in decreased secretion of TNF protein corilagin inhibits the reaction [Morphine results in increased expression of TNF protein]; TLR2 protein inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of TNF protein]]; Tunicamycin inhibits the reaction [corilagin inhibits the reaction [Morphine results in increased expression of TNF protein]] corilagin results in decreased expression of TNF protein corilagin inhibits the reaction [Doxorubicin results in increased expression of TNF protein] |
CTD |
PMID:12628509 PMID:34369273 PMID:34605098 PMID:35084093 PMID:37394652 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfsf11 |
TNF superfamily member 11 |
multiple interactions |
ISO |
[corilagin co-treated with TNFSF11 protein] results in increased expression of GSR mRNA; corilagin inhibits the reaction [TNFSF11 protein results in decreased expression of CAT mRNA]; corilagin inhibits the reaction [TNFSF11 protein results in decreased expression of HMOX1 protein]; corilagin inhibits the reaction [TNFSF11 protein results in decreased expression of NFE2L2 mRNA]; corilagin inhibits the reaction [TNFSF11 protein results in increased expression of FOS mRNA]; corilagin inhibits the reaction [TNFSF11 protein results in increased expression of FOS protein]; corilagin inhibits the reaction [TNFSF11 protein results in increased expression of NFATC1 mRNA]; corilagin inhibits the reaction [TNFSF11 protein results in increased expression of NFATC1 protein]; tin protoporphyrin IX inhibits the reaction [corilagin inhibits the reaction [TNFSF11 protein results in decreased expression of HMOX1 protein]] |
CTD |
PMID:35307913 |
|
NCBI chr15:53,673,850...53,705,325
Ensembl chr15:53,673,877...53,705,445
|
|
G |
Tnni3 |
troponin I3, cardiac type |
multiple interactions |
EXP |
corilagin inhibits the reaction [Doxorubicin results in increased expression of TNNI3 protein] |
CTD |
PMID:34369273 |
|
NCBI chr 1:69,299,900...69,303,582
Ensembl chr 1:69,299,900...69,303,580
|
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
multiple interactions |
EXP |
dioscin promotes the reaction [1-Naphthylisothiocyanate results in increased expression of ABCB11 mRNA]; dioscin promotes the reaction [1-Naphthylisothiocyanate results in increased expression of ABCB11 protein] |
CTD |
PMID:27317372 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
decreases expression |
ISO EXP |
dioscin results in decreased expression of ABCB1 mRNA; dioscin results in decreased expression of ABCB1 protein |
CTD |
PMID:24680847 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
multiple interactions |
EXP |
dioscin promotes the reaction [1-Naphthylisothiocyanate results in increased expression of ABCC2 mRNA]; dioscin promotes the reaction [1-Naphthylisothiocyanate results in increased expression of ABCC2 protein] |
CTD |
PMID:27317372 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Acadm |
acyl-CoA dehydrogenase medium chain |
multiple interactions |
EXP ISO |
dioscin inhibits the reaction [Ethanol results in decreased expression of ACADM protein] |
CTD |
PMID:24146112 |
|
NCBI chr 2:242,858,865...242,883,036
Ensembl chr 2:242,858,865...242,883,147
|
|
G |
Acads |
acyl-CoA dehydrogenase short chain |
multiple interactions |
ISO EXP |
dioscin inhibits the reaction [Ethanol results in decreased expression of ACADS protein] |
CTD |
PMID:24146112 |
|
NCBI chr12:41,493,650...41,502,897
Ensembl chr12:41,493,626...41,502,898
|
|
G |
Acox1 |
acyl-CoA oxidase 1 |
multiple interactions |
EXP ISO |
dioscin inhibits the reaction [Ethanol results in decreased expression of ACOX1 mRNA] |
CTD |
PMID:24146112 |
|
NCBI chr10:101,406,197...101,431,252
Ensembl chr10:101,406,197...101,431,232
|
|
G |
Acsl1 |
acyl-CoA synthetase long-chain family member 1 |
multiple interactions |
ISO EXP |
dioscin inhibits the reaction [Ethanol results in decreased expression of ACSL1 protein] |
CTD |
PMID:24146112 |
|
NCBI chr16:45,755,246...45,821,541
Ensembl chr16:45,755,254...45,821,541
|
|
G |
Acsl5 |
acyl-CoA synthetase long-chain family member 5 |
multiple interactions |
ISO EXP |
dioscin inhibits the reaction [Ethanol results in decreased expression of ACSL5 protein] |
CTD |
PMID:24146112 |
|
NCBI chr 1:254,289,513...254,336,608
Ensembl chr 1:254,292,521...254,336,607
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
ISO |
dioscin inhibits the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of ACTA2 protein] |
CTD |
PMID:35481609 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions decreases expression |
ISO |
dioscin inhibits the reaction [TGFB1 protein results in increased phosphorylation of AKT1 protein]; dioscin inhibits the reaction [VEGFA protein results in increased phosphorylation of AKT1 protein] dioscin inhibits the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased phosphorylation of AKT1 protein] dioscin results in decreased expression of AKT1 mRNA |
CTD |
PMID:25111127 PMID:29990575 PMID:35481609 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Aldh7a1 |
aldehyde dehydrogenase 7 family, member A1 |
multiple interactions |
ISO EXP |
dioscin inhibits the reaction [Ethanol results in decreased expression of ALDH7A1 protein] |
CTD |
PMID:24146112 |
|
NCBI chr18:50,003,242...50,042,193
Ensembl chr18:50,009,934...50,042,193
|
|
G |
Apaf1 |
apoptotic peptidase activating factor 1 |
decreases expression |
ISO |
dioscin results in decreased expression of APAF1 mRNA |
CTD |
PMID:33359023 |
|
NCBI chr 7:25,494,143...25,579,540
Ensembl chr 7:25,494,609...25,579,540
|
|
G |
Atf6 |
activating transcription factor 6 |
multiple interactions |
EXP ISO |
dioscin inhibits the reaction [Ethanol results in increased expression of ATF6 protein] |
CTD |
PMID:24146112 |
|
NCBI chr13:82,927,579...83,106,381
Ensembl chr13:82,930,034...83,107,177
|
|
G |
Bad |
BCL2-associated agonist of cell death |
increases expression |
ISO |
dioscin results in increased expression of BAD mRNA |
CTD |
PMID:33359023 |
|
NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823
|
|
G |
Bak1 |
BCL2-antagonist/killer 1 |
multiple interactions increases expression |
ISO |
dioscin inhibits the reaction [Acetaminophen results in increased expression of BAK1 protein] dioscin results in increased expression of BAK1 mRNA; dioscin results in increased expression of BAK1 protein |
CTD |
PMID:22334414 PMID:22939915 PMID:29990575 PMID:33359023 |
|
NCBI chr20:5,100,480...5,109,669
Ensembl chr20:5,100,480...5,109,264
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions increases expression |
ISO |
dioscin inhibits the reaction [Acetaminophen results in increased expression of BAX protein] dioscin results in increased expression of BAX mRNA; dioscin results in increased expression of BAX protein |
CTD |
PMID:22334414 PMID:22939915 PMID:33359023 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bbc3 |
Bcl-2 binding component 3 |
increases expression |
ISO |
dioscin results in increased expression of BBC3 mRNA; dioscin results in increased expression of BBC3 protein |
CTD |
PMID:29990575 PMID:33359023 |
|
NCBI chr 1:77,013,281...77,022,509
Ensembl chr 1:77,014,543...77,022,509
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions increases expression decreases expression |
ISO |
dioscin inhibits the reaction [Acetaminophen results in decreased expression of BCL2 protein] dioscin results in increased expression of BCL2 protein dioscin results in decreased expression of BCL2 mRNA; dioscin results in decreased expression of BCL2 protein |
CTD |
PMID:22334414 PMID:22939915 PMID:24742230 PMID:29990575 PMID:33359023 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
decreases expression |
ISO |
dioscin results in decreased expression of BCL2L1 mRNA; dioscin results in decreased expression of BCL2L1 protein |
CTD |
PMID:22334414 PMID:29990575 PMID:33359023 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479 Ensembl chr 1:141,253,523...141,303,479
|
|
G |
Bid |
BH3 interacting domain death agonist |
multiple interactions decreases expression |
ISO |
[Acetaminophen co-treated with dioscin] results in increased expression of BID protein dioscin results in decreased expression of BID mRNA; dioscin results in decreased expression of BID protein |
CTD |
PMID:22334414 PMID:22939915 |
|
NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
increases expression |
ISO |
dioscin results in increased expression of BIRC5 mRNA |
CTD |
PMID:29990575 |
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Casp3 |
caspase 3 |
multiple interactions decreases expression increases expression increases activity |
EXP ISO |
dioscin inhibits the reaction [Ethanol results in increased expression of CASP3 protein] dioscin results in decreased expression of CASP3 mRNA; dioscin results in decreased expression of CASP3 protein dioscin results in increased expression of CASP3 mRNA; dioscin results in increased expression of CASP3 protein benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [dioscin results in increased expression of CASP3 protein]; benzyloxycarbonyl-leucyl-glutamyl-histidyl-aspartic acid fluoromethyl ketone inhibits the reaction [dioscin results in increased expression of CASP3 protein] dioscin results in increased activity of CASP3 protein |
CTD |
PMID:22334414 PMID:24146112 PMID:29990575 PMID:33359023 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp7 |
caspase 7 |
increases expression |
ISO |
dioscin results in increased expression of CASP7 mRNA |
CTD |
PMID:29990575 |
|
NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Casp8 |
caspase 8 |
increases activity multiple interactions decreases expression increases expression |
ISO |
dioscin results in increased activity of CASP8 protein dioscin results in decreased expression of and results in increased cleavage of CASP8 protein dioscin results in decreased expression of CASP8 mRNA dioscin results in increased expression of CASP8 mRNA; dioscin results in increased expression of CASP8 protein |
CTD |
PMID:22334414 PMID:29990575 PMID:33359023 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
multiple interactions decreases expression increases expression |
EXP ISO |
dioscin inhibits the reaction [Ethanol results in increased expression of CASP9 protein] dioscin results in decreased expression of CASP9 mRNA; dioscin results in decreased expression of CASP9 protein dioscin results in increased expression of CASP9 mRNA; dioscin results in increased expression of CASP9 protein |
CTD |
PMID:24146112 PMID:29990575 PMID:33359023 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Ccna2 |
cyclin A2 |
decreases expression |
ISO |
dioscin results in decreased expression of CCNA2 mRNA; dioscin results in decreased expression of CCNA2 protein |
CTD |
PMID:33359023 |
|
NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577
|
|
G |
Ccnb1 |
cyclin B1 |
decreases expression |
ISO |
dioscin results in decreased expression of CCNB1 mRNA; dioscin results in decreased expression of CCNB1 protein |
CTD |
PMID:29990575 |
|
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
|
|
G |
Ccnd1 |
cyclin D1 |
increases expression decreases expression |
ISO |
dioscin results in increased expression of CCND1 mRNA dioscin results in decreased expression of CCND1 mRNA; dioscin results in decreased expression of CCND1 protein |
CTD |
PMID:29990575 PMID:33359023 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccne1 |
cyclin E1 |
decreases expression |
ISO |
dioscin results in decreased expression of CCNE1 mRNA; dioscin results in decreased expression of CCNE1 protein |
CTD |
PMID:33359023 |
|
NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
decreases expression |
ISO |
dioscin results in decreased expression of CDK1 mRNA; dioscin results in decreased expression of CDK1 protein |
CTD |
PMID:29990575 |
|
NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
decreases expression |
ISO |
dioscin results in decreased expression of CDK2 mRNA; dioscin results in decreased expression of CDK2 protein |
CTD |
PMID:33359023 |
|
NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
decreases expression |
ISO |
dioscin results in decreased expression of CDK4 mRNA |
CTD |
PMID:33359023 |
|
NCBI chr 7:62,886,124...62,889,562
Ensembl chr 7:62,883,105...62,942,403
|
|
G |
Cdk6 |
cyclin-dependent kinase 6 |
decreases expression |
ISO |
dioscin results in decreased expression of CDK6 mRNA; dioscin results in decreased expression of CDK6 protein |
CTD |
PMID:33359023 |
|
NCBI chr 4:30,637,650...30,829,688
Ensembl chr 4:30,646,460...30,829,634
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression |
ISO |
dioscin results in increased expression of CDKN1A mRNA; dioscin results in increased expression of CDKN1A protein |
CTD |
PMID:29990575 PMID:33359023 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
increases expression |
ISO |
dioscin results in increased expression of CDKN1B mRNA; dioscin results in increased expression of CDKN1B protein |
CTD |
PMID:33359023 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
increases expression |
ISO |
dioscin results in increased expression of CDKN2A mRNA; dioscin results in increased expression of CDKN2A protein |
CTD |
PMID:33359023 |
|
NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149
|
|
G |
Chek1 |
checkpoint kinase 1 |
decreases expression |
ISO |
dioscin results in decreased expression of CHEK1 mRNA; dioscin results in decreased expression of CHEK1 protein |
CTD |
PMID:33359023 |
|
NCBI chr 8:36,420,565...36,443,477
Ensembl chr 8:36,420,569...36,441,009
|
|
G |
Chek2 |
checkpoint kinase 2 |
decreases expression |
ISO |
dioscin results in decreased expression of CHEK2 mRNA; dioscin results in decreased expression of CHEK2 protein |
CTD |
PMID:29990575 |
|
NCBI chr12:45,788,823...45,821,382
Ensembl chr12:45,788,827...45,821,286
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
multiple interactions |
ISO EXP |
dioscin inhibits the reaction [Ethanol results in decreased expression of CPT1A mRNA] |
CTD |
PMID:24146112 |
|
NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055
|
|
G |
Ctnnb1 |
catenin beta 1 |
increases expression multiple interactions |
ISO |
dioscin results in increased expression of CTNNB1 mRNA; dioscin results in increased expression of CTNNB1 protein fulvestrant inhibits the reaction [dioscin results in increased expression of CTNNB1 mRNA] |
CTD |
PMID:24742230 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Cycs |
cytochrome c, somatic |
increases expression |
ISO |
dioscin results in increased expression of CYCS mRNA |
CTD |
PMID:33359023 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054 Ensembl chr18:79,651,378...79,654,054
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions |
ISO EXP |
dioscin inhibits the reaction [Acetaminophen results in increased expression of and results in increased activity of CYP2E1 protein]; dioscin inhibits the reaction [Ethanol results in increased expression of and results in increased activity of CYP2E1 protein] |
CTD |
PMID:22939915 PMID:24146112 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Dgat1 |
diacylglycerol O-acyltransferase 1 |
multiple interactions |
ISO EXP |
dioscin inhibits the reaction [Ethanol results in increased expression of DGAT1 mRNA] |
CTD |
PMID:24146112 |
|
NCBI chr 7:108,223,860...108,235,413
Ensembl chr 7:108,218,524...108,234,299
|
|
G |
Dgat2 |
diacylglycerol O-acyltransferase 2 |
multiple interactions |
ISO EXP |
dioscin inhibits the reaction [Ethanol results in increased expression of DGAT2 mRNA] |
CTD |
PMID:24146112 |
|
NCBI chr 1:153,454,078...153,484,432
Ensembl chr 1:153,454,080...153,484,428
|
|
G |
Diablo |
diablo, IAP-binding mitochondrial protein |
increases expression |
ISO |
dioscin results in increased expression of DIABLO mRNA |
CTD |
PMID:29990575 |
|
NCBI chr12:33,055,784...33,070,401
Ensembl chr12:33,055,263...33,070,387
|
|
G |
Esr1 |
estrogen receptor 1 |
increases expression multiple interactions |
ISO |
dioscin results in increased expression of ESR1 protein fulvestrant inhibits the reaction [dioscin results in increased expression of ESR1 protein] |
CTD |
PMID:24742230 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions increases expression |
ISO |
fulvestrant inhibits the reaction [dioscin results in increased expression of ESR2 protein] |
CTD |
PMID:24742230 |
|
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
Fadd |
Fas associated via death domain |
increases expression |
ISO |
dioscin results in increased expression of FADD mRNA; dioscin results in increased expression of FADD protein |
CTD |
PMID:22334414 PMID:29990575 PMID:33359023 |
|
NCBI chr 1:199,743,200...199,745,746
Ensembl chr 1:199,739,994...199,745,653
|
|
G |
Fas |
Fas cell surface death receptor |
increases expression |
ISO |
dioscin results in increased expression of FAS mRNA; dioscin results in increased expression of FAS protein |
CTD |
PMID:22334414 PMID:33359023 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Faslg |
Fas ligand |
increases expression |
ISO |
dioscin results in increased expression of FASLG mRNA; dioscin results in increased expression of FASLG protein |
CTD |
PMID:22334414 PMID:29990575 |
|
NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
|
|
G |
Foxo1 |
forkhead box O1 |
increases expression |
ISO |
dioscin results in increased expression of FOXO1 mRNA |
CTD |
PMID:33359023 |
|
NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
EXP |
dioscin inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of GPT protein] |
CTD |
PMID:27317372 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
EXP ISO |
dioscin inhibits the reaction [Ethanol results in decreased expression of GSR protein] |
CTD |
PMID:24146112 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Hmgb1 |
high mobility group box 1 |
multiple interactions |
EXP |
dioscin inhibits the reaction [Doxorubicin results in increased expression of HMGB1 protein] dioscin inhibited the reaction [thioacetamide increased expression of Hmgb1 protein in liver] |
CTD RGD |
PMID:28082111 PMID:29091898 |
RGD:15090820 |
NCBI chr12:5,972,950...5,979,658
Ensembl chr12:5,901,586...5,978,565 Ensembl chr16:5,901,586...5,978,565
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
EXP |
dioscin inhibits the reaction [Doxorubicin results in decreased expression of HMOX1 protein] dioscin inhibited the reaction [thioacetamide decreased expression of Hmox1 protein in liver] |
CTD RGD |
PMID:28082111 PMID:29091898 |
RGD:15090820 |
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions |
EXP ISO |
dioscin inhibits the reaction [Ethanol results in increased expression of HSPA5 protein] |
CTD |
PMID:24146112 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
EXP |
dioscin inhibited the reaction [thioacetamide increased expression of Icam1 protein in liver] |
RGD |
PMID:29091898 |
RGD:15090820 |
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Il13 |
interleukin 13 |
multiple interactions |
ISO |
dioscin inhibits the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of IL13 protein] |
CTD |
PMID:35481609 |
|
NCBI chr10:37,790,130...37,792,687
Ensembl chr10:37,790,130...37,792,737
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP |
dioscin inhibits the reaction [Doxorubicin results in increased expression of IL1B mRNA]; NR1H4 protein affects the reaction [dioscin inhibits the reaction [Doxorubicin results in increased expression of IL1B mRNA]] dioscin inhibited the reaction [thioacetamide increased expression of IL-1b mRNA in liver] |
CTD RGD |
PMID:28082111 PMID:29091898 |
RGD:15090820 |
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il4 |
interleukin 4 |
multiple interactions |
ISO |
dioscin inhibits the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of IL4 protein] |
CTD |
PMID:35481609 |
|
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Il5 |
interleukin 5 |
multiple interactions |
ISO |
dioscin inhibits the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of IL5 protein] |
CTD |
PMID:35481609 |
|
NCBI chr10:37,874,342...37,877,213
Ensembl chr10:37,874,342...37,877,213
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO EXP |
dioscin inhibits the reaction [Ethanol results in increased expression of IL6 mRNA] dioscin inhibited the reaction [thioacetamide increased expression of IL-6 mRNA in liver] dioscin inhibits the reaction [Doxorubicin results in increased expression of IL6 mRNA]; dioscin inhibits the reaction [Ethanol results in increased expression of IL6 mRNA]; NR1H4 protein affects the reaction [dioscin inhibits the reaction [Doxorubicin results in increased expression of IL6 mRNA]] |
CTD RGD |
PMID:24146112 PMID:28082111 PMID:29091898 |
RGD:15090820 |
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Kdr |
kinase insert domain receptor |
multiple interactions |
ISO |
dioscin inhibits the reaction [VEGFA protein results in increased phosphorylation of KDR protein] |
CTD |
PMID:25111127 |
|
NCBI chr14:32,217,871...32,261,018
Ensembl chr14:32,217,871...32,261,018
|
|
G |
Keap1 |
Kelch-like ECH-associated protein 1 |
multiple interactions |
EXP |
dioscin inhibits the reaction [Doxorubicin results in increased expression of KEAP1 protein] |
CTD |
PMID:28082111 |
|
NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862
|
|
G |
Krt18 |
keratin 18 |
multiple interactions |
ISO EXP |
dioscin inhibits the reaction [Acetaminophen results in increased expression of KRT18 protein]; dioscin inhibits the reaction [Ethanol results in increased expression of KRT18 protein] |
CTD |
PMID:22939915 PMID:24146112 |
|
NCBI chr 7:133,157,486...133,161,162
Ensembl chr 7:133,157,475...133,161,166 Ensembl chr10:133,157,475...133,161,166
|
|
G |
Lrp5 |
LDL receptor related protein 5 |
multiple interactions increases expression |
ISO |
fulvestrant inhibits the reaction [dioscin results in increased expression of LRP5 mRNA]; LRP5 protein affects the reaction [dioscin results in increased expression of TNFRSF11B mRNA]; LRP5 protein affects the reaction [dioscin results in increased expression of TNFSF11 mRNA] |
CTD |
PMID:24742230 |
|
NCBI chr 1:200,814,247...200,917,581
Ensembl chr 1:200,814,250...200,917,581
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
EXP ISO |
dioscin inhibits the reaction [Ethanol results in increased phosphorylation of MAPK1 protein] dioscin inhibits the reaction [VEGFA protein results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:24146112 PMID:25111127 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
EXP ISO |
dioscin inhibits the reaction [Ethanol results in increased phosphorylation of MAPK3 protein] dioscin inhibits the reaction [VEGFA protein results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:24146112 PMID:25111127 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
increases expression |
ISO |
dioscin results in increased expression of MAPK8 mRNA |
CTD |
PMID:29990575 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
increases expression |
ISO |
dioscin results in increased expression of MAPK9 mRNA |
CTD |
PMID:29990575 |
|
NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178
|
|
G |
Mdh1 |
malate dehydrogenase 1 |
multiple interactions |
ISO |
dioscin inhibits the reaction [Acetaminophen results in decreased expression of MDH1 protein] |
CTD |
PMID:22939915 |
|
NCBI chr14:95,630,625...95,645,920
Ensembl chr14:95,630,306...95,645,925
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
decreases expression |
ISO |
dioscin results in decreased expression of MTOR mRNA |
CTD |
PMID:29990575 |
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Muc5ac |
mucin 5AC, oligomeric mucus/gel-forming |
multiple interactions |
ISO |
dioscin inhibits the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of MUC5AC mRNA] |
CTD |
PMID:35481609 |
|
NCBI chr 1:196,864,336...196,896,475
Ensembl chr 1:196,864,336...196,896,475
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
EXP |
dioscin inhibits the reaction [Doxorubicin results in decreased expression of and affects the localization of NFE2L2 protein]; NR1H4 protein affects the reaction [dioscin inhibits the reaction [Doxorubicin results in decreased expression of NFE2L2 protein]] dioscin inhibited the reaction [thioacetamide decreased expression of Nfe2L2 protein in liver] |
CTD RGD |
PMID:28082111 PMID:29091898 |
RGD:15090820 |
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
EXP |
dioscin inhibited the reaction [thioacetamide increased expression of Nfkb1 protein in liver] |
RGD |
PMID:29091898 |
RGD:15090820 |
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
decreases degradation |
ISO |
dioscin results in decreased degradation of NFKBIA protein |
CTD |
PMID:24680847 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
EXP |
dioscin inhibited the reaction [thioacetamide decreased expression of Nqo1 protein in liver] |
RGD |
PMID:29091898 |
RGD:15090820 |
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nr0b2 |
nuclear receptor subfamily 0, group B, member 2 |
multiple interactions increases expression |
EXP |
dioscin promotes the reaction [1-Naphthylisothiocyanate results in increased expression of NR0B2 mRNA] dioscin results in increased expression of NR0B2 mRNA |
CTD |
PMID:27317372 |
|
NCBI chr 5:145,779,294...145,782,609
Ensembl chr 5:145,779,294...145,782,609
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
multiple interactions |
EXP |
dioscin inhibits the reaction [Doxorubicin results in decreased expression of NR1H4 protein]; NR1H4 protein affects the reaction [dioscin inhibits the reaction [Doxorubicin results in decreased expression of NFE2L2 protein]]; NR1H4 protein affects the reaction [dioscin inhibits the reaction [Doxorubicin results in increased expression of IL1B mRNA]]; NR1H4 protein affects the reaction [dioscin inhibits the reaction [Doxorubicin results in increased expression of IL6 mRNA]]; NR1H4 protein affects the reaction [dioscin inhibits the reaction [Doxorubicin results in increased expression of RELA protein]]; NR1H4 protein affects the reaction [dioscin inhibits the reaction [Doxorubicin results in increased expression of TNF mRNA]] dioscin inhibited the reaction [thioacetamide decreased expression of Nr1h4 protein in liver] |
CTD RGD |
PMID:28082111 PMID:29091898 |
RGD:15090820 |
NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions decreases expression increases expression |
ISO EXP |
dioscin inhibits the reaction [Ethanol results in increased expression of PARP1 protein] dioscin results in decreased expression of PARP1 mRNA; dioscin results in decreased expression of PARP1 protein dioscin results in increased expression of PARP1 mRNA |
CTD |
PMID:24146112 PMID:29990575 PMID:33359023 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pik3cb |
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit beta |
decreases expression |
ISO |
dioscin results in decreased expression of PIK3CB mRNA |
CTD |
PMID:29990575 |
|
NCBI chr 8:99,594,600...99,699,772
Ensembl chr 8:99,594,644...99,699,663
|
|
G |
Pnp |
purine nucleoside phosphorylase |
multiple interactions |
ISO |
dioscin inhibits the reaction [Acetaminophen results in decreased expression of PNP protein] |
CTD |
PMID:22939915 |
|
NCBI chr15:24,170,607...24,178,269
Ensembl chr15:24,170,602...24,203,986
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
EXP ISO |
dioscin inhibits the reaction [Ethanol results in decreased expression of PPARA protein] |
CTD |
PMID:24146112 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Prdx1 |
peroxiredoxin 1 |
multiple interactions |
ISO |
dioscin inhibits the reaction [Acetaminophen results in decreased expression of PRDX1 protein] |
CTD |
PMID:22939915 |
|
NCBI chr 5:130,147,258...130,162,856
Ensembl chr 5:130,147,204...130,162,856
|
|
G |
Prkaa1 |
protein kinase AMP-activated catalytic subunit alpha 1 |
multiple interactions |
EXP |
dioscin inhibited the reaction [thioacetamide decreased expression of Prkaa1 protein in liver] |
RGD |
PMID:29091898 |
RGD:15090820 |
NCBI chr 2:54,240,298...54,275,978
Ensembl chr 2:54,240,137...54,275,978
|
|
G |
Prkab1 |
protein kinase AMP-activated non-catalytic subunit beta 1 |
increases expression |
ISO |
dioscin results in increased expression of PRKAB1 mRNA |
CTD |
PMID:29990575 |
|
NCBI chr12:40,588,140...40,598,673
Ensembl chr12:40,588,211...40,598,661
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
EXP |
dioscin inhibited the reaction [thioacetamide increased expression of Ptgs2 protein in liver] |
RGD |
PMID:29091898 |
RGD:15090820 |
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Ptk2 |
protein tyrosine kinase 2 |
multiple interactions |
ISO |
dioscin inhibits the reaction [VEGFA protein results in increased phosphorylation of PTK2 protein] |
CTD |
PMID:25111127 |
|
NCBI chr 7:105,126,725...105,331,848
Ensembl chr 7:105,126,728...105,331,783
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP |
dioscin inhibits the reaction [Doxorubicin results in increased expression of RELA protein]; NR1H4 protein affects the reaction [dioscin inhibits the reaction [Doxorubicin results in increased expression of RELA protein]] |
CTD |
PMID:28082111 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Rgn |
regucalcin |
multiple interactions |
ISO |
dioscin inhibits the reaction [Acetaminophen results in decreased expression of RGN protein] |
CTD |
PMID:22939915 |
|
NCBI chr X:1,619,030...1,634,456
Ensembl chr X:1,619,032...1,634,450
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
decreases expression |
ISO |
dioscin results in decreased expression of RPS6KB1 mRNA |
CTD |
PMID:29990575 |
|
NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908
|
|
G |
Slc10a1 |
solute carrier family 10 member 1 |
multiple interactions |
EXP |
dioscin inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of SLC10A1 mRNA] |
CTD |
PMID:27317372 |
|
NCBI chr 6:100,613,045...100,626,670
Ensembl chr 6:100,613,045...100,626,670
|
|
G |
Slco1a4 |
solute carrier organic anion transporter family, member 1a4 |
increases expression |
EXP |
dioscin results in increased expression of SLCO1A2 mRNA |
CTD |
PMID:27317372 |
|
NCBI chr 4:174,710,004...174,764,810
Ensembl chr 4:174,710,004...175,254,573
|
|
G |
Slco1b2 |
solute carrier organic anion transporter family member 1B2 |
multiple interactions increases expression |
EXP |
dioscin inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of SLCO1B2 mRNA]; dioscin inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of SLCO1B2 protein] dioscin results in increased expression of SLCO1B2 mRNA |
CTD |
PMID:27317372 |
|
NCBI chr 4:174,551,463...174,619,988
Ensembl chr 4:174,551,480...174,619,981
|
|
G |
Src |
SRC proto-oncogene, non-receptor tyrosine kinase |
multiple interactions |
ISO |
dioscin inhibits the reaction [VEGFA protein results in increased phosphorylation of SRC protein] |
CTD |
PMID:25111127 |
|
NCBI chr 3:146,091,969...146,139,492
Ensembl chr 3:146,091,841...146,139,476
|
|
G |
Suox |
sulfite oxidase |
multiple interactions |
ISO |
dioscin inhibits the reaction [Acetaminophen results in decreased expression of SUOX protein] |
CTD |
PMID:22939915 |
|
NCBI chr 7:1,103,149...1,107,156
Ensembl chr 7:1,103,151...1,107,038
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO |
dioscin inhibits the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of TGFB1 protein] dioscin inhibits the reaction [TGFB1 protein results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:35481609 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases expression |
ISO EXP |
dioscin inhibits the reaction [[Ovalbumin co-treated with Aluminum Hydroxide] results in increased expression of TNF protein]; dioscin inhibits the reaction [Ethanol results in increased expression of TNF mRNA] dioscin inhibited the reaction [thioacetamide increased expression of Tnfa mRNA in liver] dioscin results in increased expression of TNF mRNA; dioscin results in increased expression of TNF protein dioscin inhibits the reaction [Doxorubicin results in increased expression of TNF mRNA]; dioscin inhibits the reaction [Ethanol results in increased expression of TNF mRNA]; NR1H4 protein affects the reaction [dioscin inhibits the reaction [Doxorubicin results in increased expression of TNF mRNA]] |
CTD RGD |
PMID:22334414 PMID:24146112 PMID:28082111 PMID:29990575 PMID:33359023 PMID:35481609 PMID:29091898 More...
|
RGD:15090820 |
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfrsf11b |
TNF receptor superfamily member 11B |
increases expression multiple interactions |
ISO |
dioscin results in increased expression of TNFRSF11B mRNA fulvestrant inhibits the reaction [dioscin results in increased expression of TNFRSF11B mRNA]; LRP5 protein affects the reaction [dioscin results in increased expression of TNFRSF11B mRNA] |
CTD |
PMID:24742230 |
|
NCBI chr 7:85,566,520...85,594,526
Ensembl chr 7:85,566,520...85,594,538
|
|
G |
Tnfrsf1a |
TNF receptor superfamily member 1A |
increases expression |
ISO |
dioscin results in increased expression of TNFRSF1A mRNA; dioscin results in increased expression of TNFRSF1A protein |
CTD |
PMID:22334414 PMID:29990575 PMID:33359023 |
|
NCBI chr 4:158,150,815...158,163,592
Ensembl chr 4:158,150,820...158,163,591
|
|
G |
Tnfrsf25 |
TNF receptor superfamily member 25 |
increases expression |
ISO |
dioscin results in increased expression of TNFRSF25 mRNA |
CTD |
PMID:29990575 PMID:33359023 |
|
NCBI chr 5:162,621,669...162,626,341
Ensembl chr 5:162,622,075...162,626,341
|
|
G |
Tnfsf11 |
TNF superfamily member 11 |
decreases expression multiple interactions |
ISO |
dioscin results in decreased expression of TNFSF11 mRNA fulvestrant inhibits the reaction [dioscin results in increased expression of TNFSF11 mRNA]; LRP5 protein affects the reaction [dioscin results in increased expression of TNFSF11 mRNA] |
CTD |
PMID:24742230 |
|
NCBI chr15:53,673,850...53,705,325
Ensembl chr15:53,673,877...53,705,445
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions increases expression |
ISO EXP |
dioscin inhibits the reaction [Acetaminophen results in increased expression of TRP53 protein]; dioscin inhibits the reaction [Ethanol results in increased expression of TRP53 protein] dioscin results in increased expression of TP53 mRNA; dioscin results in increased expression of TP53 protein |
CTD |
PMID:22334414 PMID:22939915 PMID:24146112 PMID:29990575 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Tradd |
TNFRSF1A-associated via death domain |
increases expression |
ISO |
dioscin results in increased expression of TRADD mRNA |
CTD |
PMID:29990575 PMID:33359023 |
|
NCBI chr19:33,136,148...33,142,714
Ensembl chr19:33,136,138...33,142,638
|
|
G |
Traf1 |
TNF receptor-associated factor 1 |
increases expression |
ISO |
dioscin results in increased expression of TRAF1 protein |
CTD |
PMID:22334414 |
|
NCBI chr 3:18,222,024...18,242,163
Ensembl chr 3:18,222,054...18,241,807
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
ISO |
dioscin inhibits the reaction [VEGFA protein results in increased phosphorylation of AKT1 protein]; dioscin inhibits the reaction [VEGFA protein results in increased phosphorylation of KDR protein]; dioscin inhibits the reaction [VEGFA protein results in increased phosphorylation of MAPK1 protein]; dioscin inhibits the reaction [VEGFA protein results in increased phosphorylation of MAPK3 protein]; dioscin inhibits the reaction [VEGFA protein results in increased phosphorylation of PTK2 protein]; dioscin inhibits the reaction [VEGFA protein results in increased phosphorylation of SRC protein] |
CTD |
PMID:25111127 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Wee1 |
WEE1 G2 checkpoint kinase |
increases expression |
ISO |
dioscin results in increased expression of WEE1 mRNA |
CTD |
PMID:29990575 |
|
NCBI chr 1:164,173,681...164,197,688
Ensembl chr 1:164,174,779...164,197,688
|
|
|
G |
Acp3 |
acid phosphatase 3 |
increases expression |
ISO |
Ellagic Acid results in increased expression of ACP3 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 8:104,905,570...104,956,146
Ensembl chr 8:104,905,586...104,954,236
|
|
G |
Acp5 |
acid phosphatase 5, tartrate resistant |
multiple interactions |
ISO |
Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of ACP5 mRNA]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of ACP5 protein] |
CTD |
PMID:32971123 |
|
NCBI chr 8:20,663,984...20,670,604
Ensembl chr 8:20,663,985...20,667,929
|
|
G |
Agt |
angiotensinogen |
multiple interactions |
EXP |
Ellagic Acid inhibits the reaction [AGT protein results in decreased abundance of NADP]; Ellagic Acid inhibits the reaction [AGT protein results in increased activity of CASP3 protein]; Ellagic Acid inhibits the reaction [AGT protein results in increased activity of RELA protein]; Ellagic Acid inhibits the reaction [AGT protein results in increased expression of AGTR1 protein]; Ellagic Acid inhibits the reaction [AGT protein results in increased expression of CYBA mRNA]; Ellagic Acid inhibits the reaction [AGT protein results in increased expression of MYH7 mRNA]; Ellagic Acid inhibits the reaction [AGT protein results in increased expression of NCF2 mRNA]; Ellagic Acid inhibits the reaction [AGT protein results in increased expression of NOS2 mRNA]; Ellagic Acid inhibits the reaction [AGT protein results in increased expression of NPPA mRNA]; Ellagic Acid inhibits the reaction [AGT protein results in increased expression of NPPB mRNA]; Ellagic Acid inhibits the reaction [AGT protein results in increased phosphorylation of MAPK1 protein]; Ellagic Acid inhibits the reaction [AGT protein results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:38356441 |
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Agtr1a |
angiotensin II receptor, type 1a |
multiple interactions |
EXP |
Ellagic Acid inhibits the reaction [AGT protein results in increased expression of AGTR1 protein] |
CTD |
PMID:38356441 |
|
NCBI chr17:34,173,446...34,226,892
Ensembl chr17:34,174,429...34,226,946
|
|
G |
Aifm1 |
apoptosis inducing factor, mitochondria associated 1 |
increases expression |
ISO |
Ellagic Acid results in increased expression of AIFM1 protein |
CTD |
PMID:23554011 |
|
NCBI chr X:127,650,223...127,689,356
Ensembl chr X:127,650,226...127,689,256
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
increases phosphorylation multiple interactions |
ISO EXP |
Ellagic Acid results in increased phosphorylation of AKT1 protein Ellagic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of AKT1 protein] |
CTD |
PMID:26986492 PMID:35236242 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Alb |
albumin |
multiple interactions affects binding |
ISO |
ALB protein promotes the reaction [Ellagic Acid results in increased activity of F12 protein] Ellagic Acid binds to ALB protein |
CTD |
PMID:6343536 PMID:25247703 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Alkbh2 |
alkB homolog 2, alpha-ketoglutarate-dependent dioxygenase |
decreases activity |
ISO |
Ellagic Acid results in decreased activity of ALKBH2 protein |
CTD |
PMID:31088072 |
|
NCBI chr12:42,494,187...42,500,929
Ensembl chr12:42,496,300...42,500,914
|
|
G |
Alpl |
alkaline phosphatase, biomineralization associated |
increases expression |
ISO |
Ellagic Acid results in increased expression of ALPL mRNA |
CTD |
PMID:38145796 |
|
NCBI chr 5:149,951,397...150,006,424
Ensembl chr 5:149,951,409...150,006,446
|
|
G |
Apaf1 |
apoptotic peptidase activating factor 1 |
decreases expression increases expression |
ISO |
Ellagic Acid results in decreased expression of APAF1 mRNA Ellagic Acid results in increased expression of APAF1 mRNA |
CTD |
PMID:12002526 PMID:35179410 |
|
NCBI chr 7:25,494,143...25,579,540
Ensembl chr 7:25,494,609...25,579,540
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
EXP |
Ellagic Acid inhibits the reaction [Aluminum Chloride results in increased expression of APP protein] |
CTD |
PMID:34944019 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Ascl1 |
achaete-scute family bHLH transcription factor 1 |
increases expression |
ISO |
Ellagic Acid results in increased expression of ASCL1 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 7:21,903,136...21,906,003
Ensembl chr 7:21,903,126...21,905,993
|
|
G |
Asns |
asparagine synthetase (glutamine-hydrolyzing) |
increases expression |
ISO |
Ellagic Acid results in increased expression of ASNS mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 4:35,784,995...35,803,474
Ensembl chr 4:35,785,237...35,803,423
|
|
G |
Atf3 |
activating transcription factor 3 |
increases expression |
ISO |
Ellagic Acid results in increased expression of ATF3 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631
|
|
G |
Atg5 |
autophagy related 5 |
increases expression |
ISO |
Ellagic Acid results in increased expression of ATG5 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr20:47,798,217...47,889,216
Ensembl chr20:47,798,290...47,889,209
|
|
G |
Bad |
BCL2-associated agonist of cell death |
increases expression |
ISO |
Ellagic Acid results in increased expression of BAD protein |
CTD |
PMID:23554011 |
|
NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions increases expression |
EXP ISO |
Ellagic Acid inhibits the reaction [sodium arsenate results in increased expression of BAX mRNA] Ellagic Acid results in increased expression of BAX mRNA |
CTD |
PMID:29854611 PMID:35179410 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
increases expression decreases expression multiple interactions |
ISO EXP |
Ellagic Acid results in increased expression of BCL2 protein Ellagic Acid results in decreased expression of BCL2 mRNA Ellagic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of BCL2 protein]; Ellagic Acid inhibits the reaction [sodium arsenate results in decreased expression of BCL2 mRNA] [Ellagic Acid co-treated with resveratrol] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of BCL2 mRNA] |
CTD |
PMID:20103723 PMID:22386815 PMID:29854611 PMID:35179410 PMID:35236242 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bmp6 |
bone morphogenetic protein 6 |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of BMP6 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr17:26,318,121...26,469,691
Ensembl chr17:26,318,569...26,470,365
|
|
G |
Brf1 |
BRF1 general transcription factor IIIB subunit |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of BRF1 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 6:132,034,378...132,081,313
Ensembl chr 6:132,037,272...132,081,278
|
|
G |
Calr |
calreticulin |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of CALR mRNA |
CTD |
PMID:12002526 |
|
NCBI chr19:23,308,525...23,313,420
Ensembl chr19:23,308,351...23,313,414
|
|
G |
Casp3 |
caspase 3 |
increases expression multiple interactions increases activity decreases activity decreases expression |
ISO EXP |
Ellagic Acid results in increased expression of CASP3 mRNA Ellagic Acid inhibits the reaction [AGT protein results in increased activity of CASP3 protein]; Ellagic Acid inhibits the reaction [Aluminum Chloride results in increased expression of CASP3 protein]; Ellagic Acid inhibits the reaction [Carbon Tetrachloride results in decreased expression of CASP3 protein]; Ellagic Acid inhibits the reaction [Doxorubicin results in increased expression of CASP3 protein]; Ellagic Acid inhibits the reaction [sodium arsenate results in increased activity of CASP3 protein]; Ellagic Acid inhibits the reaction [Streptozocin results in increased expression of CASP3 protein]; Ellagic Acid promotes the reaction [sinapinic acid inhibits the reaction [Streptozocin results in increased expression of CASP3 protein]]; sinapinic acid promotes the reaction [Ellagic Acid inhibits the reaction [Streptozocin results in increased expression of CASP3 protein]] Ellagic Acid results in increased expression of and results in increased activity of CASP3 protein Ellagic Acid results in increased activity of CASP3 protein Ellagic Acid results in decreased activity of CASP3 protein Ellagic Acid results in decreased expression of CASP3 mRNA |
CTD |
PMID:12002526 PMID:22386815 PMID:23554011 PMID:23811531 PMID:28815802 PMID:29854611 PMID:34661493 PMID:34944019 PMID:35236242 PMID:38356441 More...
|
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
ISO |
Ellagic Acid results in increased expression of and results in increased activity of CASP9 protein |
CTD |
PMID:23554011 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
increases activity multiple interactions |
EXP |
Ellagic Acid results in increased activity of CAT protein Ellagic Acid inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in decreased activity of CAT protein]; Ellagic Acid inhibits the reaction [Carbon Tetrachloride results in decreased activity of CAT protein]; Ellagic Acid inhibits the reaction [chromium hexavalent ion results in decreased activity of CAT protein]; Ellagic Acid inhibits the reaction [sodium arsenite results in decreased activity of CAT protein] |
CTD |
PMID:20074268 PMID:24877639 PMID:29864931 PMID:35236242 PMID:36108929 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
decreases secretion |
ISO |
Ellagic Acid results in decreased secretion of CCL2 protein |
CTD |
PMID:20816778 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccng1 |
cyclin G1 |
decreases expression |
EXP |
ellagic acid inhibits the reaction [estrogen increases expression of Ccng1 mRNA and protein in rat mammary tissue] |
RGD |
PMID:23791885 |
RGD:151356928 |
NCBI chr10:25,176,231...25,182,604
Ensembl chr10:25,176,234...25,181,641
|
|
G |
Cd14 |
CD14 molecule |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of CD14 mRNA |
CTD |
PMID:20816778 |
|
NCBI chr18:28,335,522...28,337,383
Ensembl chr18:28,335,340...28,337,261
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of CDK1 protein |
CTD |
PMID:23554011 |
|
NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions increases expression |
ISO |
[resveratrol co-treated with Ellagic Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of CDKN1A mRNA] [Ellagic Acid co-treated with Quercetin] results in increased expression of CDKN1A mRNA; Ellagic Acid promotes the reaction [Quercetin results in increased expression of CDKN1A protein]; pifithrin inhibits the reaction [Ellagic Acid promotes the reaction [Quercetin results in increased expression of CDKN1A protein]] Ellagic Acid results in increased expression of CDKN1A protein |
CTD |
PMID:15735102 PMID:20103723 PMID:23554011 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
increases expression |
ISO |
Ellagic Acid results in increased expression of COL1A1 mRNA; Ellagic Acid results in increased expression of COL1A1 protein |
CTD |
PMID:38145796 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Ctsd |
cathepsin D |
multiple interactions |
EXP |
Ellagic Acid inhibits the reaction [Isoproterenol results in increased activity of CTSD protein] |
CTD |
PMID:21762681 |
|
NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488
|
|
G |
Ctsk |
cathepsin K |
multiple interactions |
ISO |
Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of CTSK mRNA]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of CTSK protein] |
CTD |
PMID:32971123 |
|
NCBI chr 2:183,058,586...183,069,551
Ensembl chr 2:183,058,569...183,069,550
|
|
G |
Cyba |
cytochrome b-245 alpha chain |
multiple interactions |
EXP |
Ellagic Acid inhibits the reaction [AGT protein results in increased expression of CYBA mRNA] |
CTD |
PMID:38356441 |
|
NCBI chr19:50,487,598...50,495,669
Ensembl chr19:50,487,597...50,495,721
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
decreases expression decreases activity |
ISO |
Ellagic Acid results in decreased expression of CYP1A1 mRNA Ellagic Acid results in decreased activity of CYP1A1 protein |
CTD |
PMID:19329757 PMID:20816778 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
decreases activity multiple interactions |
ISO |
Ellagic Acid results in decreased activity of CYP1B1 protein [Ellagic Acid co-treated with Plant Extracts] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of CYP1B1 mRNA]; [Ellagic Acid co-treated with resveratrol] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of CYP1B1 mRNA] |
CTD |
PMID:19329757 PMID:20103723 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Daxx |
death-domain associated protein |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of DAXX mRNA |
CTD |
PMID:12002526 |
|
NCBI chr20:4,970,090...4,976,145
Ensembl chr20:4,970,092...4,975,843
|
|
G |
Dffa |
DNA fragmentation factor subunit alpha |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of DFFA mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 5:159,540,715...159,553,639
Ensembl chr 5:159,540,715...159,553,633
|
|
G |
E4f1 |
E4F transcription factor 1 |
increases expression |
ISO |
Ellagic Acid results in increased expression of E4F1 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr10:13,471,478...13,495,018
Ensembl chr10:13,474,456...13,485,974
|
|
G |
Egr3 |
early growth response 3 |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of EGR3 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr15:45,150,335...45,156,052
Ensembl chr15:45,150,567...45,154,627
|
|
G |
Endog |
endonuclease G |
increases expression |
ISO |
Ellagic Acid results in increased expression of ENDOG protein |
CTD |
PMID:23554011 |
|
NCBI chr 3:13,449,113...13,451,715
Ensembl chr 3:13,449,086...13,451,932
|
|
G |
Ep300 |
E1A binding protein p300 |
increases expression |
ISO |
Ellagic Acid results in increased expression of EP300 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 7:113,108,476...113,178,529
Ensembl chr 7:113,106,247...113,136,088 Ensembl chr 7:113,106,247...113,136,088
|
|
G |
Eps15 |
epidermal growth factor receptor pathway substrate 15 |
increases expression |
ISO |
Ellagic Acid results in increased expression of EPS15 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 5:124,045,865...124,146,221
Ensembl chr 5:124,045,926...124,146,221
|
|
G |
Ezh1 |
enhancer of zeste 1 polycomb repressive complex 2 subunit |
increases expression |
ISO |
Ellagic Acid results in increased expression of EZH1 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr10:86,126,023...86,162,001
Ensembl chr10:86,126,015...86,161,921
|
|
G |
F12 |
coagulation factor XII |
multiple interactions increases activity |
ISO |
ALB protein promotes the reaction [Ellagic Acid results in increased activity of F12 protein] |
CTD |
PMID:6343536 |
|
NCBI chr17:9,207,683...9,215,530
Ensembl chr17:9,207,683...9,215,530
|
|
G |
Fgfr1 |
Fibroblast growth factor receptor 1 |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of FGFR1 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr16:66,491,930...66,547,161
Ensembl chr16:66,494,042...66,547,350
|
|
G |
Flna |
filamin A |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of FLNA mRNA |
CTD |
PMID:12002526 |
|
NCBI chr X:152,007,758...152,034,266
Ensembl chr X:152,007,758...152,031,052
|
|
G |
Fn1 |
fibronectin 1 |
multiple interactions |
EXP |
Ellagic Acid inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of FN1 protein] |
CTD |
PMID:24877639 |
|
NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
[Ellagic Acid co-treated with Plant Extracts] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of FOS mRNA]; [Ellagic Acid co-treated with Resveratrol] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of FOS mRNA]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of FOS mRNA]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of FOS protein] |
CTD |
PMID:20103723 PMID:32971123 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
G6pd |
glucose-6-phosphate dehydrogenase |
decreases activity |
ISO |
Ellagic Acid results in decreased activity of G6PD protein |
CTD |
PMID:25130191 |
|
NCBI chr X:152,201,081...152,220,863
Ensembl chr X:152,201,098...152,220,801
|
|
G |
Gal |
galanin and GMAP prepropeptide |
multiple interactions |
EXP |
Ellagic Acid inhibits the reaction [phosalone results in increased activity of GAL protein] |
CTD |
PMID:27965107 |
|
NCBI chr 1:200,650,439...200,655,302
Ensembl chr 1:200,650,439...200,654,959
|
|
G |
Gpld1 |
glycosylphosphatidylinositol specific phospholipase D1 |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of GPLD1 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr17:40,084,427...40,132,035
Ensembl chr17:40,084,617...40,126,939
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
EXP ISO |
Ellagic Acid inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased expression of GPT protein]; Ellagic Acid inhibits the reaction [sodium arsenite results in increased expression of GPT protein] Ellagic Acid inhibits the reaction [Diquat results in increased activity of GPT protein] |
CTD |
PMID:24877639 PMID:29935397 PMID:35268077 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
multiple interactions |
EXP ISO |
Ellagic Acid inhibits the reaction [sodium arsenite results in decreased expression of GPX1 mRNA] Ellagic Acid inhibits the reaction [Diquat results in decreased expression of GPX1 mRNA] |
CTD |
PMID:29935397 PMID:35268077 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
EXP |
Ellagic Acid inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in decreased activity of GSR protein] |
CTD |
PMID:24877639 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Gsta4 |
glutathione S-transferase alpha 4 |
increases expression |
ISO |
Ellagic Acid results in increased expression of GSTA4 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 8:79,066,967...79,084,193
Ensembl chr 8:79,066,934...79,084,182
|
|
G |
Gstt1 |
glutathione S-transferase theta 1 |
affects expression |
EXP |
Ellagic Acid affects the expression of GSTT1 protein |
CTD |
PMID:9855024 |
|
NCBI chr20:12,856,613...12,873,586
Ensembl chr20:12,856,669...12,873,585
|
|
G |
Gtf2e2 |
general transcription factor IIE subunit 2 |
increases expression |
ISO |
Ellagic Acid results in increased expression of GTF2E2 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr16:58,399,307...58,449,467
Ensembl chr16:58,399,107...58,449,371
|
|
G |
Gtf2h4 |
general transcription factor 2H subunit 4 |
increases expression |
ISO |
Ellagic Acid results in increased expression of GTF2H4 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr20:3,071,328...3,076,990
Ensembl chr20:3,071,328...3,076,984
|
|
G |
Gusb |
glucuronidase, beta |
multiple interactions |
EXP |
Ellagic Acid inhibits the reaction [Isoproterenol results in increased activity of GUSB protein] |
CTD |
PMID:21762681 |
|
NCBI chr12:26,701,188...26,714,718
Ensembl chr12:26,697,951...26,726,905
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of HIF1A mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hlcs |
holocarboxylase synthetase |
decreases activity |
ISO |
Ellagic Acid results in decreased activity of HLCS protein |
CTD |
PMID:26303405 |
|
NCBI chr11:33,455,806...33,635,197
Ensembl chr11:33,455,809...33,624,222
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression multiple interactions |
ISO |
Ellagic Acid results in increased expression of HMOX1 mRNA; Ellagic Acid results in increased expression of HMOX1 protein Ellagic Acid inhibits the reaction [Diquat results in decreased expression of HMOX1 mRNA] [Paraquat co-treated with Ellagic Acid] results in increased expression of HMOX1 mRNA; [Paraquat co-treated with Ellagic Acid] results in increased expression of HMOX1 protein |
CTD |
PMID:22386815 PMID:23546295 PMID:35268077 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hras |
HRas proto-oncogene, GTPase |
multiple interactions |
ISO |
[Ellagic Acid co-treated with Plant Extracts] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased mutagenesis of HRAS gene]; [Ellagic Acid co-treated with resveratrol] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased mutagenesis of HRAS gene] |
CTD |
PMID:20103723 |
|
NCBI chr 1:196,290,127...196,299,823
Ensembl chr 1:196,296,263...196,300,615
|
|
G |
Ier2 |
immediate early response 2 |
increases expression |
ISO |
Ellagic Acid results in increased expression of IER2 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr19:23,494,551...23,496,075
Ensembl chr19:23,494,184...23,499,211
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
EXP |
Ellagic Acid inhibits the reaction [sodium arsenate results in increased expression of IFNG mRNA]; Ellagic Acid inhibits the reaction [sodium arsenate results in increased expression of IFNG protein] |
CTD |
PMID:29854611 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Igfbp2 |
insulin-like growth factor binding protein 2 |
increases expression |
ISO |
Ellagic Acid results in increased expression of IGFBP2 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 9:74,415,574...74,442,945
Ensembl chr 9:74,415,546...74,442,937
|
|
G |
Igfbp4 |
insulin-like growth factor binding protein 4 |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of IGFBP4 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr10:83,995,253...84,007,272
Ensembl chr10:83,989,591...84,007,225
|
|
G |
Il1b |
interleukin 1 beta |
decreases expression multiple interactions |
ISO EXP |
Ellagic Acid results in decreased expression of IL1B mRNA Ellagic Acid inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of IL1B protein]; Ellagic Acid inhibits the reaction [Glucose results in increased expression of IL1B protein]; Ellagic Acid inhibits the reaction [Isoproterenol results in increased expression of IL1B mRNA]; Ellagic Acid inhibits the reaction [phosalone results in increased expression of IL1B protein]; Ellagic Acid inhibits the reaction [sodium arsenate results in increased expression of IL1B mRNA]; Ellagic Acid inhibits the reaction [sodium arsenite results in increased expression of IL1B protein] Ellagic Acid inhibits the reaction [IL1B protein results in increased secretion of CXCL8 protein] |
CTD |
PMID:18377686 PMID:20816778 PMID:21762681 PMID:24877639 PMID:27965107 PMID:29455002 PMID:29854611 PMID:29864931 More...
|
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il1r1 |
interleukin 1 receptor type 1 |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of IL1R1 mRNA |
CTD |
PMID:20816778 |
|
NCBI chr 9:42,504,917...42,580,958
Ensembl chr 9:42,504,735...42,579,937
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP |
Ellagic Acid inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of IL6 protein]; Ellagic Acid inhibits the reaction [Glucose results in increased expression of IL6 protein]; Ellagic Acid inhibits the reaction [Isoproterenol results in increased expression of IL6 mRNA]; Ellagic Acid inhibits the reaction [phosalone results in increased expression of IL6 protein] |
CTD |
PMID:21762681 PMID:24877639 PMID:27965107 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Inpp5d |
inositol polyphosphate-5-phosphatase D |
increases expression |
ISO |
Ellagic Acid results in increased expression of INPP5D mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 9:88,287,680...88,392,748
Ensembl chr 9:88,287,677...88,392,746
|
|
G |
Iqgap2 |
IQ motif containing GTPase activating protein 2 |
increases expression |
ISO |
Ellagic Acid results in increased expression of IQGAP2 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 2:26,894,836...27,170,270
Ensembl chr 2:26,894,825...27,170,279
|
|
G |
Irf9 |
interferon regulatory factor 9 |
increases expression |
ISO |
Ellagic Acid results in increased expression of IRF9 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr15:29,095,474...29,101,924
Ensembl chr15:29,095,789...29,101,236
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of JUN mRNA; Ellagic Acid results in decreased expression of JUN protein modified form |
CTD |
PMID:23811531 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Klk1c10 |
kallikrein 1-related peptidase C10 |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of KLK3 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 1:94,402,993...94,407,052
Ensembl chr 1:94,402,993...94,407,052
|
|
G |
Litaf |
lipopolysaccharide-induced TNF factor |
increases expression |
ISO |
Ellagic Acid results in increased expression of LITAF mRNA |
CTD |
PMID:12002526 |
|
NCBI chr10:4,656,308...4,692,981
Ensembl chr10:4,625,552...4,692,763
|
|
G |
Map1a |
microtubule-associated protein 1A |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of MAP1A mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 3:108,263,217...108,283,936
Ensembl chr 3:108,263,151...108,282,899
|
|
G |
Map3k1 |
mitogen-activated protein kinase kinase kinase 1 |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of MAP3K1 mRNA; Ellagic Acid results in decreased expression of MAP3K1 protein |
CTD |
PMID:23811531 |
|
NCBI chr 2:43,348,572...43,414,706
Ensembl chr 2:43,350,098...43,414,463
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO EXP |
Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased phosphorylation of MAPK1 protein] Ellagic Acid inhibits the reaction [AGT protein results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:32971123 PMID:38356441 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk11 |
mitogen-activated protein kinase 11 |
increases expression |
ISO |
Ellagic Acid results in increased expression of MAPK11 mRNA |
CTD |
PMID:23811531 |
|
NCBI chr 7:120,218,471...120,225,488
Ensembl chr 7:120,218,478...120,225,395
|
|
G |
Mapk14 |
mitogen activated protein kinase 14 |
multiple interactions |
EXP |
Ellagic Acid inhibits the reaction [phosalone results in increased expression of MAPK14 protein] |
CTD |
PMID:27965107 |
|
NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO EXP |
Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased phosphorylation of MAPK3 protein] Ellagic Acid inhibits the reaction [AGT protein results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:32971123 PMID:38356441 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
ISO |
[Ellagic Acid co-treated with Quercetin] results in increased phosphorylation of MAPK8 protein |
CTD |
PMID:15735102 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
multiple interactions |
ISO |
[Ellagic Acid co-treated with Quercetin] results in increased phosphorylation of MAPK9 protein |
CTD |
PMID:15735102 |
|
NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178
|
|
G |
Mgst1 |
microsomal glutathione S-transferase 1 |
decreases activity |
EXP |
Ellagic Acid results in decreased activity of MGST1 protein |
CTD |
PMID:16125204 |
|
NCBI chr 4:171,029,666...171,044,893
Ensembl chr 4:171,029,630...171,044,892
|
|
G |
Mir140 |
microRNA 140 |
multiple interactions |
EXP |
ellagic acid inhibits the reaction [hypoxia and acute myocardial infarction decreases expression of mir140 RNA in cardiac muscle cells] |
RGD |
PMID:28922712 |
RGD:329347824 |
NCBI chr19:35,465,577...35,465,675
Ensembl chr19:35,465,577...35,465,675
|
|
G |
Mmd |
monocyte to macrophage differentiation-associated |
increases expression |
ISO |
Ellagic Acid results in increased expression of MMD mRNA |
CTD |
PMID:12002526 |
|
NCBI chr10:75,073,278...75,101,528
Ensembl chr10:75,073,365...75,101,528
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions decreases expression decreases activity |
ISO |
Ellagic Acid results in decreased activity of and results in decreased secretion of MMP2 protein; zinc chloride inhibits the reaction [Ellagic Acid results in decreased activity of and results in decreased secretion of MMP2 protein] Ellagic Acid results in decreased expression of MMP2 mRNA Ellagic Acid results in decreased activity of MMP2 protein |
CTD |
PMID:21573219 PMID:35179410 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
decreases expression decreases activity |
ISO |
Ellagic Acid results in decreased expression of MMP9 mRNA Ellagic Acid results in decreased activity of MMP9 protein |
CTD |
PMID:35179410 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Myh7 |
myosin heavy chain 7 |
multiple interactions |
EXP |
Ellagic Acid inhibits the reaction [AGT protein results in increased expression of MYH7 mRNA] |
CTD |
PMID:38356441 |
|
NCBI chr15:28,446,550...28,469,888
Ensembl chr15:28,446,550...28,468,217
|
|
G |
Ncf2 |
neutrophil cytosolic factor 2 |
multiple interactions |
EXP |
Ellagic Acid inhibits the reaction [AGT protein results in increased expression of NCF2 mRNA] |
CTD |
PMID:38356441 |
|
NCBI chr13:64,955,622...64,986,144
Ensembl chr13:64,955,503...64,986,277
|
|
G |
Nfatc1 |
nuclear factor of activated T-cells 1 |
multiple interactions |
ISO |
Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of NFATC1 mRNA]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of NFATC1 protein] |
CTD |
PMID:32971123 |
|
NCBI chr18:74,046,422...74,156,041
Ensembl chr18:74,046,904...74,156,028
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
affects localization multiple interactions increases expression affects response to substance |
ISO EXP |
Ellagic Acid affects the localization of NFE2L2 protein Ellagic Acid inhibits the reaction [Carbon Tetrachloride results in decreased expression of NFE2L2 protein] Ellagic Acid results in increased expression of NFE2L2 mRNA [Ellagic Acid co-treated with Diquat] results in increased expression of NFE2L2 mRNA; Ellagic Acid inhibits the reaction [Diquat results in decreased expression of NFE2L2 mRNA]; Ellagic Acid inhibits the reaction [sodium arsenate results in decreased expression of NFE2L2 mRNA] [Paraquat co-treated with Ellagic Acid] results in increased expression of and affects the localization of NFE2L2 protein; [Paraquat co-treated with Ellagic Acid] results in increased expression of NFE2L2 mRNA; Ellagic Acid results in increased expression of and affects the localization of NFE2L2 protein Ellagic Acid results in increased expression of NFE2L2 mRNA; Ellagic Acid results in increased expression of NFE2L2 protein NFE2L2 protein affects the susceptibility to Ellagic Acid |
CTD |
PMID:22386815 PMID:23546295 PMID:30503583 PMID:35236242 PMID:35268077 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkb2 |
nuclear factor kappa B subunit 2 |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of NFKB2 mRNA |
CTD |
PMID:12002526 PMID:35179410 |
|
NCBI chr 1:245,164,586...245,173,225
Ensembl chr 1:245,165,950...245,173,213
|
|
G |
Nnat |
neuronatin |
increases expression |
ISO |
Ellagic Acid results in increased expression of NNAT mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 3:146,225,941...146,228,868
Ensembl chr 3:146,226,407...146,228,834
|
|
G |
Nop56 |
NOP56 ribonucleoprotein |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of NOP56 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 3:117,476,963...117,481,847
Ensembl chr 3:117,477,053...117,481,841
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions decreases expression |
EXP ISO |
Ellagic Acid inhibits the reaction [AGT protein results in increased expression of NOS2 mRNA]; Ellagic Acid inhibits the reaction [Doxorubicin results in increased expression of NOS2 protein] Ellagic Acid results in decreased expression of NOS2 mRNA |
CTD |
PMID:28815802 PMID:35179410 PMID:38356441 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Npas2 |
neuronal PAS domain protein 2 |
increases expression |
ISO |
Ellagic Acid results in increased expression of NPAS2 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 9:41,463,361...41,642,322
Ensembl chr 9:41,463,830...41,642,320
|
|
G |
Nppa |
natriuretic peptide A |
multiple interactions |
EXP |
Ellagic Acid inhibits the reaction [AGT protein results in increased expression of NPPA mRNA] |
CTD |
PMID:38356441 |
|
NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351
|
|
G |
Nppb |
natriuretic peptide B |
multiple interactions |
EXP |
Ellagic Acid inhibits the reaction [AGT protein results in increased expression of NPPB mRNA] |
CTD |
PMID:38356441 |
|
NCBI chr 5:158,416,813...158,418,175
Ensembl chr 5:158,416,866...158,418,168
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
increases expression multiple interactions |
ISO |
Ellagic Acid results in increased expression of NQO1 mRNA; Ellagic Acid results in increased expression of NQO1 protein Ellagic Acid inhibits the reaction [Diquat results in decreased expression of NQO1 mRNA] [Paraquat co-treated with Ellagic Acid] results in increased expression of NQO1 mRNA; [Paraquat co-treated with Ellagic Acid] results in increased expression of NQO1 protein |
CTD |
PMID:23546295 PMID:35268077 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
increases activity |
ISO |
Ellagic Acid results in increased activity of NR1I3 protein |
CTD |
PMID:21821919 |
|
NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906
|
|
G |
Parg |
poly (ADP-ribose) glycohydrolase |
decreases activity |
ISO |
Ellagic Acid results in decreased activity of PARG protein |
CTD |
PMID:19840838 |
|
NCBI chr16:7,436,429...7,544,276
Ensembl chr16:7,436,476...7,544,273
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions |
EXP |
Ellagic Acid inhibits the reaction [Rotenone results in increased cleavage of PARP1 protein] |
CTD |
PMID:25247703 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pcna |
proliferating cell nuclear antigen |
multiple interactions |
ISO |
[resveratrol co-treated with Ellagic Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of PCNA mRNA] |
CTD |
PMID:20103723 |
|
NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
|
|
G |
Pdia2 |
protein disulfide isomerase family A, member 2 |
multiple interactions |
EXP |
Ellagic Acid inhibits the reaction [Rotenone results in increased nitrosation of and results in decreased activity of PDIA2 protein] |
CTD |
PMID:25247703 |
|
NCBI chr10:15,215,824...15,218,937
Ensembl chr10:15,215,824...15,220,931
|
|
G |
Pgd |
phosphogluconate dehydrogenase |
decreases activity |
ISO |
Ellagic Acid results in decreased activity of PGD protein |
CTD |
PMID:25130191 |
|
NCBI chr 5:159,582,746...159,598,945
Ensembl chr 5:159,561,271...159,742,778
|
|
G |
Pla2g2a |
phospholipase A2 group IIA |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of PLA2G2A mRNA |
CTD |
PMID:20816778 |
|
NCBI chr 5:151,076,442...151,079,019
Ensembl chr 5:151,076,442...151,079,014
|
|
G |
Plp2 |
proteolipid protein 2 |
increases expression |
ISO |
Ellagic Acid results in increased expression of PLP2 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr X:14,834,249...14,837,648
Ensembl chr X:14,834,231...14,838,514
|
|
G |
Pml |
PML nuclear body scaffold |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of PML mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 8:58,627,347...58,661,927
Ensembl chr 8:58,628,837...58,658,971
|
|
G |
Ppard |
peroxisome proliferator-activated receptor delta |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of PPARD mRNA |
CTD |
PMID:12002526 |
|
NCBI chr20:6,298,785...6,363,970
Ensembl chr20:6,298,785...6,363,968
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
increases expression |
ISO |
Ellagic Acid results in increased expression of PPARG protein |
CTD |
PMID:23811531 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
multiple interactions decreases expression |
ISO |
Ellagic Acid inhibits the reaction [sodium arsenate results in increased expression of PPARGC1A mRNA] Ellagic Acid results in decreased expression of PPARGC1A mRNA |
CTD |
PMID:30503583 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Prkg1 |
protein kinase cGMP-dependent 1 |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of PRKG1 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 1:228,409,605...229,638,794
Ensembl chr 1:228,408,947...229,639,080
|
|
G |
Ptn |
pleiotrophin |
decreases expression increases expression |
ISO |
Ellagic Acid results in decreased expression of PTN mRNA Ellagic Acid results in increased expression of PTN mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 4:65,293,731...65,375,572
Ensembl chr 4:65,293,734...65,375,456
|
|
G |
Ptprn2 |
protein tyrosine phosphatase, receptor type N2 |
increases expression |
ISO |
Ellagic Acid results in increased expression of PTPRN2 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 6:137,439,572...138,191,575
Ensembl chr 6:137,439,540...138,191,575
|
|
G |
Ran |
RAN, member RAS oncogene family |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of RAN mRNA |
CTD |
PMID:12002526 |
|
NCBI chr12:27,674,049...27,678,598
Ensembl chr12:27,674,050...27,678,276
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
multiple interactions |
EXP |
Ellagic Acid inhibits the reaction [phosalone results in increased expression of RB1 mRNA]; Ellagic Acid inhibits the reaction [phosalone results in increased expression of RB1 protein] |
CTD |
PMID:27965107 |
|
NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302
|
|
G |
Reck |
reversion-inducing-cysteine-rich protein with kazal motifs |
increases expression multiple interactions |
ISO |
Ellagic Acid results in increased expression of RECK mRNA; Ellagic Acid results in increased expression of RECK protein zinc chloride inhibits the reaction [Ellagic Acid results in increased expression of RECK mRNA]; zinc chloride inhibits the reaction [Ellagic Acid results in increased expression of RECK protein] |
CTD |
PMID:21573219 |
|
NCBI chr 5:58,102,961...58,169,516
Ensembl chr 5:58,102,981...58,169,502
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
decreases expression multiple interactions |
ISO EXP |
Ellagic Acid results in decreased expression of RELA mRNA Ellagic Acid inhibits the reaction [TNF protein affects the localization of and results in increased activity of RELA protein] Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased phosphorylation of RELA protein] Ellagic Acid inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of RELA protein]; Ellagic Acid inhibits the reaction [AGT protein results in increased activity of RELA protein]; Ellagic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of RELA protein]; Ellagic Acid inhibits the reaction [Glucose results in increased expression of RELA protein]; Ellagic Acid inhibits the reaction [phosalone results in increased expression of RELA protein] |
CTD |
PMID:12002526 PMID:24877639 PMID:27473819 PMID:27965107 PMID:32971123 PMID:35236242 PMID:38356441 More...
|
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Rgs5 |
regulator of G-protein signaling 5 |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of RGS5 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr13:81,848,254...81,885,053
Ensembl chr13:81,836,304...81,885,518
|
|
G |
Runx2 |
RUNX family transcription factor 2 |
increases expression |
ISO |
Ellagic Acid results in increased expression of RUNX2 mRNA; Ellagic Acid results in increased expression of RUNX2 protein |
CTD |
PMID:38145796 |
|
NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167
|
|
G |
Scd |
stearoyl-CoA desaturase |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of SCD mRNA |
CTD |
PMID:20816778 |
|
NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562
|
|
G |
Septin2 |
septin 2 |
increases expression |
ISO |
Ellagic Acid results in increased expression of SEPTIN2 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 9:94,018,141...94,051,386
Ensembl chr 9:94,018,208...94,051,386
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions |
EXP |
Ellagic Acid inhibits the reaction [Aluminum Chloride results in decreased expression of SOD1 mRNA]; Ellagic Acid inhibits the reaction [Aluminum Chloride results in decreased expression of SOD1 protein] |
CTD |
PMID:34944019 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions |
EXP |
Ellagic Acid inhibits the reaction [sodium arsenite results in decreased expression of SOD2 mRNA] |
CTD |
PMID:29935397 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Sod3 |
superoxide dismutase 3 |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of SOD3 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr14:58,610,104...58,615,845
Ensembl chr14:58,609,958...58,615,990
|
|
G |
Sp7 |
Sp7 transcription factor |
increases expression |
ISO |
Ellagic Acid results in increased expression of SP7 mRNA; Ellagic Acid results in increased expression of SP7 protein |
CTD |
PMID:38145796 |
|
NCBI chr 7:133,484,609...133,494,788
Ensembl chr 7:133,484,609...133,494,847
|
|
G |
Spp1 |
secreted phosphoprotein 1 |
increases expression |
ISO |
Ellagic Acid results in increased expression of SPP1 mRNA; Ellagic Acid results in increased expression of SPP1 protein |
CTD |
PMID:38145796 |
|
NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162
|
|
G |
Src |
SRC proto-oncogene, non-receptor tyrosine kinase |
multiple interactions |
ISO |
Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of SRC mRNA]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of SRC protein] |
CTD |
PMID:32971123 |
|
NCBI chr 3:146,091,969...146,139,492
Ensembl chr 3:146,091,841...146,139,476
|
|
G |
Star |
steroidogenic acute regulatory protein |
increases expression multiple interactions |
ISO |
Ellagic Acid results in increased expression of STAR mRNA Ellagic Acid inhibits the reaction [sodium arsenate results in decreased expression of STAR mRNA] |
CTD |
PMID:30503583 |
|
NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
increases expression decreases expression |
ISO |
Ellagic Acid results in increased expression of STAT3 mRNA Ellagic Acid results in decreased expression of STAT3 mRNA |
CTD |
PMID:12002526 PMID:20816778 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Taf1c |
TATA-box binding protein associated factor, RNA polymerase 1 subunit C |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of TAF1C mRNA |
CTD |
PMID:12002526 |
|
NCBI chr19:47,652,451...47,658,971
Ensembl chr19:47,652,452...47,658,971
|
|
G |
Tcf12 |
transcription factor 12 |
increases expression |
ISO |
Ellagic Acid results in increased expression of TCF12 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 8:72,490,447...72,799,265
Ensembl chr 8:72,492,567...72,799,201
|
|
G |
Tert |
telomerase reverse transcriptase |
multiple interactions increases expression |
ISO EXP |
Ellagic Acid inhibits the reaction [Estradiol results in increased expression of TERT mRNA alternative form] Ellagic Acid inhibits the reaction [phosalone results in decreased activity of TERT protein] Ellagic Acid results in increased expression of TERT mRNA alternative form |
CTD |
PMID:19501078 PMID:27965107 |
|
NCBI chr 1:29,637,213...29,659,561
Ensembl chr 1:29,637,506...29,659,561
|
|
G |
Tfam |
transcription factor A, mitochondrial |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of TFAM mRNA |
CTD |
PMID:12002526 |
|
NCBI chr20:17,356,243...17,368,293
Ensembl chr20:17,356,197...17,368,292
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
increases expression multiple interactions |
ISO EXP |
Ellagic Acid results in increased expression of TGFB1 mRNA Ellagic Acid inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of TGFB1 protein] |
CTD |
PMID:12002526 PMID:24877639 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions decreases expression |
EXP ISO |
Ellagic Acid inhibits the reaction [[Streptozocin co-treated with Dietary Fats] results in increased expression of TNF protein]; Ellagic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of TNF protein]; Ellagic Acid inhibits the reaction [chromium hexavalent ion results in increased expression of TNF protein]; Ellagic Acid inhibits the reaction [Doxorubicin results in increased expression of TNF protein]; Ellagic Acid inhibits the reaction [Glucose results in increased expression of TNF protein]; Ellagic Acid inhibits the reaction [Isoproterenol results in increased expression of TNF mRNA]; Ellagic Acid inhibits the reaction [phosalone results in increased expression of TNF protein]; Ellagic Acid inhibits the reaction [sodium arsenate results in increased expression of TNF mRNA]; Ellagic Acid inhibits the reaction [sodium arsenate results in increased expression of TNF protein]; Ellagic Acid inhibits the reaction [sodium arsenite results in increased expression of TNF protein] Ellagic Acid inhibits the reaction [TNF protein affects the localization of and results in increased activity of RELA protein]; Ellagic Acid inhibits the reaction [TNF protein results in increased activity of and affects the secretion of CXCL8 protein] Ellagic Acid results in decreased expression of TNF mRNA |
CTD |
PMID:21762681 PMID:24877639 PMID:27473819 PMID:27965107 PMID:28815802 PMID:29455002 PMID:29854611 PMID:29864931 PMID:35179410 PMID:35236242 PMID:36108929 More...
|
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfrsf11a |
TNF receptor superfamily member 11A |
multiple interactions affects binding |
ISO |
Ellagic Acid inhibits the reaction [TNFSF11 protein binds to TNFRSF11A protein] Ellagic Acid binds to TNFRSF11A protein |
CTD |
PMID:32971123 |
|
NCBI chr13:21,928,370...21,986,719
Ensembl chr13:21,928,408...21,986,695
|
|
G |
Tnfsf11 |
TNF superfamily member 11 |
multiple interactions affects binding |
ISO |
Ellagic Acid inhibits the reaction [TNFSF11 protein binds to TNFRSF11A protein]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of ACP5 mRNA]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of ACP5 protein]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of CTSK mRNA]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of CTSK protein]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of FOS mRNA]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of FOS protein]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of NFATC1 mRNA]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of NFATC1 protein]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of SRC mRNA]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased expression of SRC protein]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased phosphorylation of MAPK1 protein]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased phosphorylation of MAPK3 protein]; Ellagic Acid inhibits the reaction [TNFSF11 protein results in increased phosphorylation of RELA protein] Ellagic Acid binds to TNFSF11 protein |
CTD |
PMID:32971123 |
|
NCBI chr15:53,673,850...53,705,325
Ensembl chr15:53,673,877...53,705,445
|
|
G |
Tnnt2 |
troponin T2, cardiac type |
multiple interactions |
EXP |
Ellagic Acid inhibits the reaction [Isoproterenol results in increased expression of TNNT2 protein] |
CTD |
PMID:21762681 |
|
NCBI chr13:47,267,325...47,285,390
Ensembl chr13:47,267,204...47,285,388
|
|
G |
Tp53 |
tumor protein p53 |
increases expression multiple interactions |
ISO EXP |
Ellagic Acid results in increased expression of TP53 mRNA; Ellagic Acid results in increased expression of TP53 protein Ellagic Acid promotes the reaction [Quercetin results in increased phosphorylation of TP53 protein]; pifithrin inhibits the reaction [Ellagic Acid promotes the reaction [Quercetin results in increased phosphorylation of TP53 protein]] Ellagic Acid inhibits the reaction [phosalone results in increased expression of TP53 mRNA]; Ellagic Acid inhibits the reaction [phosalone results in increased expression of TP53 protein] |
CTD |
PMID:15735102 PMID:23554011 PMID:27965107 PMID:35179410 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Ugp2 |
UDP-glucose pyrophosphorylase 2 |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of UGP2 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr14:95,456,330...95,497,483
Ensembl chr14:95,456,330...95,496,830
|
|
G |
Usp4 |
ubiquitin specific peptidase 4 |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of USP4 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 8:109,035,402...109,079,382
Ensembl chr 8:109,036,099...109,080,427
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
EXP |
Ellagic Acid inhibits the reaction [Carbon Tetrachloride results in increased expression of VEGFA protein] |
CTD |
PMID:35236242 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Wars1 |
tryptophanyl-tRNA synthetase 1 |
increases expression |
ISO |
Ellagic Acid results in increased expression of WARS1 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 6:127,776,088...127,807,273
Ensembl chr 6:127,776,090...127,807,269
|
|
G |
Wee1 |
WEE1 G2 checkpoint kinase |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of WEE1 protein |
CTD |
PMID:23554011 |
|
NCBI chr 1:164,173,681...164,197,688
Ensembl chr 1:164,174,779...164,197,688
|
|
G |
Zbtb16 |
zinc finger and BTB domain containing 16 |
decreases expression |
ISO |
Ellagic Acid results in decreased expression of ZBTB16 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr 8:48,989,376...49,177,011
Ensembl chr 8:48,994,566...49,177,011
|
|
G |
Zmym2 |
zinc finger MYM-type containing 2 |
increases expression |
ISO |
Ellagic Acid results in increased expression of ZMYM2 mRNA |
CTD |
PMID:12002526 |
|
NCBI chr15:31,035,835...31,108,945
Ensembl chr15:31,035,838...31,109,357
|
|
|
G |
Tyr |
tyrosinase |
decreases expression |
ISO |
decaprenoic acid results in decreased expression of TYR protein |
CTD |
PMID:23286867 |
|
NCBI chr 1:141,115,036...141,210,207
Ensembl chr 1:141,115,036...141,210,207
|
|
|
G |
Afp |
alpha-fetoprotein |
affects binding |
EXP |
isoliquiritigenin binds to AFP protein |
CTD |
PMID:23013281 |
|
NCBI chr14:17,573,412...17,591,476
Ensembl chr14:17,573,412...17,591,480
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions |
ISO |
isoliquiritigenin inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene affects the localization of AHR protein] |
CTD |
PMID:25110319 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
decreases response to substance multiple interactions decreases phosphorylation |
ISO |
AKT1 protein modified form results in decreased susceptibility to isoliquiritigenin isoliquiritigenin inhibits the reaction [INS1 protein results in increased phosphorylation of AKT1 protein] 20-hydroxyeicosa-5(Z),14(Z)-dienoic acid inhibits the reaction [isoliquiritigenin results in decreased activity of AKT1 protein]; 20-hydroxyeicosa-5(Z),14(Z)-dienoic acid inhibits the reaction [isoliquiritigenin results in decreased phosphorylation of and results in decreased activity of AKT1 protein]; AKT1 protein modified form inhibits the reaction [isoliquiritigenin results in decreased expression of MMP2 mRNA]; AKT1 protein modified form inhibits the reaction [isoliquiritigenin results in decreased expression of MMP2 protein]; AKT1 protein modified form inhibits the reaction [isoliquiritigenin results in decreased expression of MMP9 mRNA]; AKT1 protein modified form inhibits the reaction [isoliquiritigenin results in decreased expression of MMP9 protein]; AKT1 protein modified form inhibits the reaction [isoliquiritigenin results in increased cleavage of CASP3 protein]; AKT1 protein modified form inhibits the reaction [isoliquiritigenin results in increased cleavage of CASP9 protein]; CAY 10580 inhibits the reaction [isoliquiritigenin results in decreased phosphorylation of and results in decreased activity of AKT1 protein]; Dinoprostone inhibits the reaction [isoliquiritigenin results in decreased activity of AKT1 protein]; Dinoprostone inhibits the reaction [isoliquiritigenin results in decreased phosphorylation of and results in decreased activity of AKT1 protein]; isoliquiritigenin results in decreased phosphorylation of and results in decreased activity of AKT1 protein; Leukotriene B4 inhibits the reaction [isoliquiritigenin results in decreased activity of AKT1 protein] isoliquiritigenin results in decreased phosphorylation of AKT1 protein |
CTD |
PMID:23747687 PMID:25094029 PMID:27117918 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Arg1 |
arginase 1 |
multiple interactions |
ISO |
isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ARG1 mRNA]; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ARG1 protein] |
CTD |
PMID:25026504 |
|
NCBI chr 1:20,475,878...20,488,422
Ensembl chr 1:20,475,968...20,488,422
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression |
ISO |
isoliquiritigenin results in increased expression of BAX mRNA; isoliquiritigenin results in increased expression of BAX protein |
CTD |
PMID:11055382 PMID:27702603 PMID:38311047 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases phosphorylation |
ISO |
isoliquiritigenin results in decreased phosphorylation of BCL2 protein |
CTD |
PMID:23747687 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
decreases expression decreases phosphorylation |
ISO |
isoliquiritigenin results in decreased expression of BCL2L1 protein isoliquiritigenin results in decreased phosphorylation of BCL2L1 protein |
CTD |
PMID:11055382 PMID:15729620 PMID:23747687 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479 Ensembl chr 1:141,253,523...141,303,479
|
|
G |
Birc2 |
baculoviral IAP repeat-containing 2 |
decreases expression |
ISO |
isoliquiritigenin results in decreased expression of BIRC2 protein |
CTD |
PMID:15729620 |
|
NCBI chr 8:4,968,856...4,989,325
Ensembl chr 8:4,968,842...4,988,732
|
|
G |
Birc3 |
baculoviral IAP repeat-containing 3 |
decreases expression |
ISO |
isoliquiritigenin results in decreased expression of BIRC3 protein |
CTD |
PMID:15729620 |
|
NCBI chr 8:5,000,844...5,028,470
Ensembl chr 8:5,000,845...5,015,802
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases expression increases activity increases cleavage |
ISO |
20-hydroxyeicosa-5(Z),14(Z)-dienoic acid inhibits the reaction [isoliquiritigenin results in increased cleavage of CASP3 protein]; AKT1 protein modified form inhibits the reaction [isoliquiritigenin results in increased cleavage of CASP3 protein]; benzyloxycarbonyl-leucyl-glutamyl-histidyl-aspartic acid fluoromethyl ketone inhibits the reaction [isoliquiritigenin results in increased cleavage of CASP3 protein]; CAY 10580 inhibits the reaction [isoliquiritigenin results in increased cleavage of CASP3 protein]; Dinoprostone inhibits the reaction [isoliquiritigenin results in increased cleavage of CASP3 protein]; isoliquiritigenin results in increased cleavage of and results in increased activity of CASP3 protein isoliquiritigenin results in increased expression of CASP3 mRNA isoliquiritigenin results in increased activity of CASP3 protein |
CTD |
PMID:15729620 PMID:16158945 PMID:23747687 PMID:25094029 PMID:38311047 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
increases activity |
ISO |
isoliquiritigenin results in increased activity of CASP8 protein |
CTD |
PMID:16158945 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
multiple interactions increases expression increases activity increases cleavage |
ISO |
20-hydroxyeicosa-5(Z),14(Z)-dienoic acid inhibits the reaction [isoliquiritigenin results in increased cleavage of CASP9 protein]; AKT1 protein modified form inhibits the reaction [isoliquiritigenin results in increased cleavage of CASP9 protein]; CAY 10580 inhibits the reaction [isoliquiritigenin results in increased cleavage of CASP9 protein]; Dinoprostone inhibits the reaction [isoliquiritigenin results in increased cleavage of CASP9 protein]; isoliquiritigenin results in increased cleavage of and results in increased activity of CASP9 protein isoliquiritigenin results in increased expression of CASP9 mRNA isoliquiritigenin results in increased activity of CASP9 protein |
CTD |
PMID:16158945 PMID:23747687 PMID:25094029 PMID:38311047 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions increases expression |
EXP ISO |
isoliquiritigenin inhibits the reaction [Carbon Tetrachloride results in decreased activity of CAT protein] isoliquiritigenin results in increased expression of CAT mRNA isoliquiritigenin inhibits the reaction [Paroxetine results in decreased activity of CAT protein] |
CTD |
PMID:25450236 PMID:36740106 PMID:38311047 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cckar |
cholecystokinin A receptor |
multiple interactions increases expression |
ISO |
fulvestrant inhibits the reaction [isoliquiritigenin results in increased expression of CCKAR mRNA] |
CTD |
PMID:27702603 |
|
NCBI chr14:57,292,397...57,300,747
Ensembl chr14:57,292,397...57,300,747
|
|
G |
Ccnd2 |
cyclin D2 |
decreases expression |
ISO |
isoliquiritigenin results in decreased expression of CCND2 mRNA |
CTD |
PMID:27702603 |
|
NCBI chr 4:159,966,883...159,989,261
Ensembl chr 4:159,962,363...159,989,495
|
|
G |
Ccne2 |
cyclin E2 |
decreases expression |
ISO |
isoliquiritigenin results in decreased expression of CCNE2 mRNA |
CTD |
PMID:27702603 |
|
NCBI chr 5:24,285,078...24,298,258
Ensembl chr 5:24,284,922...24,297,632
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression |
ISO |
isoliquiritigenin results in increased expression of CDKN1A mRNA; isoliquiritigenin results in increased expression of CDKN1A protein |
CTD |
PMID:27702603 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
decreases expression |
ISO |
isoliquiritigenin results in decreased expression of CDKN1B mRNA |
CTD |
PMID:27702603 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Cdkn1c |
cyclin-dependent kinase inhibitor 1C |
decreases expression |
ISO |
isoliquiritigenin results in decreased expression of CDKN1C mRNA |
CTD |
PMID:27702603 |
|
NCBI chr 1:198,655,394...198,658,097
Ensembl chr 1:198,655,407...198,658,048
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
multiple interactions |
ISO |
isoliquiritigenin inhibits the reaction [INS1 protein results in increased expression of CEBPA protein] |
CTD |
PMID:27117918 |
|
NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412
|
|
G |
Chuk |
component of inhibitor of nuclear factor kappa B kinase complex |
multiple interactions |
ISO |
isoliquiritigenin inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased phosphorylation of CHUK protein] |
CTD |
PMID:18295200 |
|
NCBI chr 1:242,959,539...242,995,066
Ensembl chr 1:242,959,760...242,995,065
|
|
G |
Ctsb |
cathepsin B |
decreases expression |
ISO |
isoliquiritigenin results in decreased expression of CTSB protein |
CTD |
PMID:38311047 |
|
NCBI chr15:37,389,636...37,410,508
Ensembl chr15:37,389,629...37,410,500
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
multiple interactions |
ISO |
isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CXCL10 mRNA] |
CTD |
PMID:25026504 |
|
NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
decreases expression |
ISO |
isoliquiritigenin results in decreased expression of CYP17A1 mRNA |
CTD |
PMID:27773742 |
|
NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
decreases expression |
ISO |
isoliquiritigenin results in decreased expression of CYP19A1 mRNA |
CTD |
PMID:27773742 |
|
NCBI chr 8:54,552,978...54,580,375
Ensembl chr 8:54,553,165...54,580,758
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
isoliquiritigenin inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of CYP1A1 mRNA]; isoliquiritigenin inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of CYP1A1 protein]; isoliquiritigenin inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA] |
CTD |
PMID:25110319 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions decreases activity |
ISO |
isoliquiritigenin inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of CYP1A2 mRNA]; isoliquiritigenin inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A2 mRNA] isoliquiritigenin results in decreased activity of CYP1A2 protein |
CTD |
PMID:25110319 PMID:29753067 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
multiple interactions increases expression |
ISO |
isoliquiritigenin inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of CYP1B1 mRNA]; isoliquiritigenin inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of CYP1B1 protein]; isoliquiritigenin inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1B1 mRNA]; isoliquiritigenin promotes the reaction [[TNF protein co-treated with IFNG protein] results in increased expression of CYP1B1 mRNA]; isoliquiritigenin promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1B1 mRNA] isoliquiritigenin results in increased expression of CYP1B1 mRNA |
CTD |
PMID:25110319 PMID:26134484 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp2c6 |
cytochrome P450, family 2, subfamily C, polypeptide 6 |
decreases activity |
ISO |
isoliquiritigenin results in decreased activity of CYP2C19 protein |
CTD |
PMID:29753067 |
|
NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions |
EXP |
isoliquiritigenin inhibits the reaction [Carbon Tetrachloride results in decreased expression of CYP2E1 mRNA]; isoliquiritigenin inhibits the reaction [Carbon Tetrachloride results in decreased expression of CYP2E1 protein] |
CTD |
PMID:25450236 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
decreases activity |
ISO |
isoliquiritigenin results in decreased activity of CYP3A4 protein |
CTD |
PMID:29753067 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions |
EXP |
isoliquiritigenin inhibits the reaction [Cisplatin results in increased expression of DDIT3 mRNA] |
CTD |
PMID:37561086 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Ern1 |
endoplasmic reticulum to nucleus signaling 1 |
multiple interactions |
EXP |
isoliquiritigenin inhibits the reaction [Cisplatin results in increased expression of ERN1 mRNA] |
CTD |
PMID:37561086 |
|
NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029
|
|
G |
Fabp4 |
fatty acid binding protein 4 |
multiple interactions |
ISO |
isoliquiritigenin inhibits the reaction [INS1 protein results in increased expression of FABP4 protein] |
CTD |
PMID:27117918 |
|
NCBI chr 2:91,580,879...91,585,567
Ensembl chr 2:91,580,885...91,585,578
|
|
G |
Foxo3 |
forkhead box O3 |
decreases expression |
ISO |
isoliquiritigenin results in decreased expression of FOXO3 mRNA |
CTD |
PMID:38311047 |
|
NCBI chr20:45,669,708...45,764,606
Ensembl chr20:45,672,995...45,764,561
|
|
G |
Gadd45gip1 |
GADD45G interacting protein 1 |
increases expression |
ISO |
isoliquiritigenin results in increased expression of GADD45GIP1 mRNA |
CTD |
PMID:27702603 |
|
NCBI chr19:23,320,662...23,323,211
Ensembl chr19:23,320,159...23,323,236
|
|
G |
Gfap |
glial fibrillary acidic protein |
multiple interactions |
ISO |
isoliquiritigenin inhibits the reaction [Methamphetamine results in increased expression of GFAP protein] |
CTD |
PMID:19834288 |
|
NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
ISO |
isoliquiritigenin inhibits the reaction [Paroxetine results in increased activity of GPT protein] |
CTD |
PMID:36740106 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
decreases expression |
ISO |
isoliquiritigenin results in decreased expression of GPX1 mRNA |
CTD |
PMID:38311047 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
EXP |
isoliquiritigenin inhibits the reaction [Cisplatin results in decreased activity of GSR protein] |
CTD |
PMID:37561086 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Havcr1 |
hepatitis A virus cellular receptor 1 |
multiple interactions |
EXP |
isoliquiritigenin inhibits the reaction [Cisplatin results in increased expression of HAVCR1 protein] |
CTD |
PMID:37561086 |
|
NCBI chr10:31,118,667...31,151,730
Ensembl chr10:31,119,088...31,151,698
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression |
ISO |
isoliquiritigenin results in increased expression of HMOX1 protein |
CTD |
PMID:23942037 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hsd17b1 |
hydroxysteroid (17-beta) dehydrogenase 1 |
decreases expression |
ISO |
isoliquiritigenin results in decreased expression of HSD17B1 mRNA |
CTD |
PMID:27773742 |
|
NCBI chr10:86,009,728...86,011,928
Ensembl chr10:86,009,728...86,011,927
|
|
G |
Hsp90b1 |
heat shock protein 90 beta family member 1 |
multiple interactions |
EXP |
[isoliquiritigenin co-treated with Cisplatin] results in increased expression of HSP90B1 protein |
CTD |
PMID:37561086 |
|
NCBI chr 7:21,110,431...21,124,762
Ensembl chr 7:21,110,457...21,124,788
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions increases expression |
EXP |
[Cisplatin co-treated with isoliquiritigenin] results in increased expression of HSPA5 mRNA isoliquiritigenin results in increased expression of HSPA5 mRNA |
CTD |
PMID:37561086 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IFNG protein]; isoliquiritigenin inhibits the reaction [IFNG protein results in increased abundance of Nitrites] isoliquiritigenin promotes the reaction [[TNF protein co-treated with IFNG protein] results in increased expression of CYP1B1 mRNA] |
CTD |
PMID:23942037 PMID:25026504 PMID:26134484 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
ISO |
isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of IL10 protein] |
CTD |
PMID:25026504 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il1rn |
interleukin 1 receptor antagonist |
multiple interactions |
ISO |
isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of IL1RN mRNA]; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of IL1RN protein] |
CTD |
PMID:25026504 |
|
NCBI chr 3:7,111,567...7,127,451
Ensembl chr 3:7,111,550...7,127,445
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of IL6 mRNA]; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of IL6 protein]; isoliquiritigenin inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of IL6 mRNA]; isoliquiritigenin inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of IL6 protein] |
CTD |
PMID:18295200 PMID:25026504 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ins1 |
insulin 1 |
multiple interactions |
ISO |
isoliquiritigenin inhibits the reaction [INS1 protein results in decreased activity of and results in increased oxidation of PTPN1 protein]; isoliquiritigenin inhibits the reaction [INS1 protein results in increased expression of CEBPA protein]; isoliquiritigenin inhibits the reaction [INS1 protein results in increased expression of FABP4 protein]; isoliquiritigenin inhibits the reaction [INS1 protein results in increased expression of PPARG protein]; isoliquiritigenin inhibits the reaction [INS1 protein results in increased expression of SLC2A4 protein]; isoliquiritigenin inhibits the reaction [INS1 protein results in increased phosphorylation of AKT1 protein]; isoliquiritigenin inhibits the reaction [INS1 protein results in increased phosphorylation of INSR protein] |
CTD |
PMID:27117918 |
|
NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536
|
|
G |
Insr |
insulin receptor |
multiple interactions |
ISO |
isoliquiritigenin inhibits the reaction [INS1 protein results in increased phosphorylation of INSR protein] |
CTD |
PMID:27117918 |
|
NCBI chr12:1,193,193...1,330,976
Ensembl chr12:1,197,100...1,330,883
|
|
G |
Itgam |
integrin subunit alpha M |
multiple interactions increases expression |
ISO |
TEMPOL-H inhibits the reaction [isoliquiritigenin results in increased expression of ITGAM protein] |
CTD |
PMID:24369695 |
|
NCBI chr 1:182,659,047...182,709,501
Ensembl chr 1:182,659,000...182,709,503
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
decreases expression |
ISO |
isoliquiritigenin results in decreased expression of MAP1LC3B protein |
CTD |
PMID:38311047 |
|
NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690 Ensembl chr16:49,665,791...49,677,690
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
isoliquiritigenin inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:18295200 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
isoliquiritigenin inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:18295200 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Melk |
maternal embryonic leucine zipper kinase |
decreases expression |
ISO |
isoliquiritigenin results in decreased expression of MELK mRNA; isoliquiritigenin results in decreased expression of MELK protein |
CTD |
PMID:36893906 |
|
NCBI chr 5:58,540,393...58,600,562
Ensembl chr 5:58,540,449...58,600,937
|
|
G |
Mfn2 |
mitofusin 2 |
increases expression |
EXP |
isoliquiritigenin results in increased expression of MFN2 protein |
CTD |
PMID:37561086 |
|
NCBI chr 5:158,304,285...158,335,502
Ensembl chr 5:158,304,287...158,335,342
|
|
G |
Mki67 |
marker of proliferation Ki-67 |
decreases expression |
ISO |
isoliquiritigenin results in decreased expression of MKI67 mRNA; isoliquiritigenin results in decreased expression of MKI67 protein |
CTD |
PMID:27702603 |
|
NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions decreases expression |
ISO |
20-hydroxyeicosa-5(Z),14(Z)-dienoic acid inhibits the reaction [isoliquiritigenin results in decreased expression of MMP2 mRNA]; 20-hydroxyeicosa-5(Z),14(Z)-dienoic acid inhibits the reaction [isoliquiritigenin results in decreased expression of MMP2 protein]; AKT1 protein modified form inhibits the reaction [isoliquiritigenin results in decreased expression of MMP2 mRNA]; AKT1 protein modified form inhibits the reaction [isoliquiritigenin results in decreased expression of MMP2 protein]; CAY 10580 inhibits the reaction [isoliquiritigenin results in decreased expression of MMP2 mRNA]; CAY 10580 inhibits the reaction [isoliquiritigenin results in decreased expression of MMP2 protein]; Dinoprostone inhibits the reaction [isoliquiritigenin results in decreased expression of MMP2 mRNA]; Dinoprostone inhibits the reaction [isoliquiritigenin results in decreased expression of MMP2 protein] isoliquiritigenin results in decreased expression of MMP2 mRNA; isoliquiritigenin results in decreased expression of MMP2 protein |
CTD |
PMID:25094029 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions decreases expression |
ISO |
20-hydroxyeicosa-5(Z),14(Z)-dienoic acid inhibits the reaction [isoliquiritigenin results in decreased expression of MMP9 mRNA]; 20-hydroxyeicosa-5(Z),14(Z)-dienoic acid inhibits the reaction [isoliquiritigenin results in decreased expression of MMP9 protein]; AKT1 protein modified form inhibits the reaction [isoliquiritigenin results in decreased expression of MMP9 mRNA]; AKT1 protein modified form inhibits the reaction [isoliquiritigenin results in decreased expression of MMP9 protein]; CAY 10580 inhibits the reaction [isoliquiritigenin results in decreased expression of MMP9 mRNA]; CAY 10580 inhibits the reaction [isoliquiritigenin results in decreased expression of MMP9 protein]; Dinoprostone inhibits the reaction [isoliquiritigenin results in decreased expression of MMP9 mRNA]; Dinoprostone inhibits the reaction [isoliquiritigenin results in decreased expression of MMP9 protein] isoliquiritigenin results in decreased expression of MMP9 mRNA; isoliquiritigenin results in decreased expression of MMP9 protein |
CTD |
PMID:25094029 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mrc1 |
mannose receptor, C type 1 |
multiple interactions |
ISO |
isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of MRC1 mRNA]; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of MRC1 protein] |
CTD |
PMID:25026504 |
|
NCBI chr17:77,249,187...77,330,857
Ensembl chr17:77,249,187...77,330,857
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
decreases expression |
ISO |
isoliquiritigenin results in decreased expression of NFE2L2 mRNA |
CTD |
PMID:38311047 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
ISO |
isoliquiritigenin inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 affects the localization of NFKB1 protein] |
CTD |
PMID:18295200 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
increases expression multiple interactions decreases phosphorylation |
ISO |
isoliquiritigenin results in increased expression of NFKBIA protein isoliquiritigenin inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased degradation of and results in increased phosphorylation of NFKBIA protein] isoliquiritigenin results in decreased phosphorylation of NFKBIA protein |
CTD |
PMID:15729620 PMID:18295200 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of NOS2 mRNA]; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of NOS2 protein]; isoliquiritigenin inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of NOS2 mRNA]; isoliquiritigenin inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of NOS2 protein]; isoliquiritigenin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]; isoliquiritigenin inhibits the reaction [Methamphetamine results in increased expression of NOS2 protein] |
CTD |
PMID:18295200 PMID:19834288 PMID:25026504 PMID:26134484 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
increases expression |
ISO |
isoliquiritigenin results in increased expression of NQO1 protein |
CTD |
PMID:26473469 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
increases activity increases expression |
ISO |
isoliquiritigenin results in increased activity of NR1I2 protein isoliquiritigenin results in increased expression of NR1I2 mRNA |
CTD |
PMID:29933105 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage multiple interactions |
ISO |
isoliquiritigenin results in increased cleavage of PARP1 protein benzyloxycarbonyl-leucyl-glutamyl-histidyl-aspartic acid fluoromethyl ketone inhibits the reaction [isoliquiritigenin results in increased cleavage of PARP1 protein] |
CTD |
PMID:23747687 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pdk1 |
pyruvate dehydrogenase kinase 1 |
decreases phosphorylation |
ISO |
isoliquiritigenin results in decreased phosphorylation of PDK1 protein |
CTD |
PMID:25094029 |
|
NCBI chr 3:56,705,824...56,733,040
Ensembl chr 3:56,705,871...56,733,038
|
|
G |
Pla2g5 |
phospholipase A2, group V |
decreases expression |
ISO |
isoliquiritigenin results in decreased expression of PLA2G5 mRNA |
CTD |
PMID:23747687 |
|
NCBI chr 5:151,041,339...151,109,433
Ensembl chr 5:151,041,340...151,062,658
|
|
G |
Pou5f1 |
POU class 5 homeobox 1 |
increases expression |
ISO |
isoliquiritigenin results in increased expression of POU5F1 mRNA |
CTD |
PMID:38311047 |
|
NCBI chr20:3,223,128...3,227,891
Ensembl chr20:3,223,129...3,227,891
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
ISO |
isoliquiritigenin inhibits the reaction [INS1 protein results in increased expression of PPARG protein] |
CTD |
PMID:27117918 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ptger4 |
prostaglandin E receptor 4 |
decreases expression |
ISO |
isoliquiritigenin results in decreased expression of PTGER4 mRNA; isoliquiritigenin results in decreased expression of PTGER4 protein |
CTD |
PMID:25094029 |
|
NCBI chr 2:54,330,563...54,347,451
Ensembl chr 2:54,335,424...54,346,670
|
|
G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
decreases expression |
ISO |
isoliquiritigenin results in decreased expression of PTGS1 mRNA |
CTD |
PMID:25094029 |
|
NCBI chr 3:19,584,015...19,605,589
Ensembl chr 3:19,584,015...19,605,586
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
decreases expression multiple interactions |
ISO EXP |
isoliquiritigenin results in decreased expression of PTGS2 mRNA isoliquiritigenin inhibits the reaction [Carbon Tetrachloride results in increased expression of PTGS2 protein] isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PTGS2 mRNA]; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PTGS2 protein]; isoliquiritigenin inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of PTGS2 mRNA]; isoliquiritigenin inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of PTGS2 protein] |
CTD |
PMID:18295200 PMID:23747687 PMID:25026504 PMID:25450236 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Ptpn1 |
protein tyrosine phosphatase, non-receptor type 1 |
multiple interactions |
ISO |
isoliquiritigenin inhibits the reaction [INS1 protein results in decreased activity of and results in increased oxidation of PTPN1 protein] |
CTD |
PMID:27117918 |
|
NCBI chr 3:156,638,811...156,687,503
Ensembl chr 3:156,638,769...156,687,504
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
affects localization multiple interactions decreases activity |
ISO |
isoliquiritigenin affects the localization of RELA protein isoliquiritigenin inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 affects the localization of RELA protein] isoliquiritigenin results in decreased activity of RELA protein |
CTD |
PMID:15729620 PMID:18295200 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Sirt1 |
sirtuin 1 |
increases expression |
ISO |
isoliquiritigenin results in increased expression of SIRT1 mRNA |
CTD |
PMID:38311047 |
|
NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260
|
|
G |
Slc2a1 |
solute carrier family 2 member 1 |
multiple interactions decreases activity |
ISO |
isoliquiritigenin inhibits the reaction [SLC2A1 protein affects the transport of Glucose] isoliquiritigenin results in decreased activity of SLC2A1 protein |
CTD |
PMID:14642735 |
|
NCBI chr 5:132,717,196...132,745,416
Ensembl chr 5:132,717,196...132,745,416
|
|
G |
Slc2a4 |
solute carrier family 2 member 4 |
multiple interactions |
ISO |
isoliquiritigenin inhibits the reaction [INS1 protein results in increased expression of SLC2A4 protein] |
CTD |
PMID:27117918 |
|
NCBI chr10:54,666,015...54,671,581
Ensembl chr10:54,666,015...54,671,565
|
|
G |
Slc6a3 |
solute carrier family 6 member 3 |
multiple interactions |
ISO |
isoliquiritigenin inhibits the reaction [Methamphetamine results in decreased expression of SLC6A3 protein] |
CTD |
PMID:19834288 |
|
NCBI chr 1:29,709,443...29,750,413
Ensembl chr 1:29,709,443...29,750,413
|
|
G |
Slco1c1 |
solute carrier organic anion transporter family, member 1c1 |
multiple interactions decreases activity |
EXP |
[isoliquiritigenin results in decreased activity of SLCO1B1 protein] which results in decreased uptake of Bosentan; [isoliquiritigenin results in decreased activity of SLCO1B1 protein] which results in decreased uptake of Methotrexate |
CTD |
PMID:32259555 |
|
NCBI chr 4:174,466,621...174,513,290
Ensembl chr 4:174,466,631...174,513,289
|
|
G |
Sod2 |
superoxide dismutase 2 |
affects response to substance increases expression |
ISO |
SOD2 protein affects the susceptibility to isoliquiritigenin isoliquiritigenin results in increased expression of SOD2 mRNA |
CTD |
PMID:23526725 PMID:38311047 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Star |
steroidogenic acute regulatory protein |
increases expression |
ISO |
isoliquiritigenin results in increased expression of STAR mRNA |
CTD |
PMID:27773742 |
|
NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions |
ISO |
isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased phosphorylation of STAT3 protein] |
CTD |
PMID:25026504 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO |
isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of TGFB1 protein] |
CTD |
PMID:25026504 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO EXP |
isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TNF protein]; isoliquiritigenin inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of TNF mRNA]; isoliquiritigenin inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of TNF protein] isoliquiritigenin promotes the reaction [[TNF protein co-treated with IFNG protein] results in increased expression of CYP1B1 mRNA] isoliquiritigenin inhibits the reaction [Carbon Tetrachloride results in increased expression of TNF protein] |
CTD |
PMID:18295200 PMID:25026504 PMID:25450236 PMID:26134484 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tp53 |
tumor protein p53 |
increases expression |
ISO |
isoliquiritigenin results in increased expression of TRP53 mRNA |
CTD |
PMID:27702603 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase family 1 member A1 |
increases glucuronidation |
ISO |
UGT1A1 protein results in increased glucuronidation of isoliquiritigenin |
CTD |
PMID:14557274 |
|
NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a9 |
UDP glucuronosyltransferase family 1 member A9 |
increases glucuronidation |
ISO |
UGT1A9 protein results in increased glucuronidation of isoliquiritigenin |
CTD |
PMID:14557274 |
|
NCBI chr 9:88,696,981...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Xbp1 |
X-box binding protein 1 |
multiple interactions |
EXP |
isoliquiritigenin inhibits the reaction [Cisplatin results in increased expression of XBP1 mRNA] |
CTD |
PMID:37561086 |
|
NCBI chr14:80,390,629...80,395,713
Ensembl chr14:80,390,643...80,395,693
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases transport increases activity multiple interactions decreases expression increases expression |
ISO |
ABCB1 protein results in increased transport of 3-methylquercetin 3-methylquercetin results in increased activity of ABCB1 protein 3-methylquercetin inhibits the reaction [ABCB1 protein results in decreased uptake of Rhodamine 123]; 3-methylquercetin promotes the reaction [Elacridar inhibits the reaction [ABCB1 protein results in decreased uptake of Rhodamine 123]]; 3-methylquercetin promotes the reaction [Quercetin results in increased activity of ABCB1 protein] 3-methylquercetin results in decreased expression of ABCB1 protein 3-methylquercetin results in increased expression of ABCB1 mRNA |
CTD |
PMID:15969930 PMID:26238175 PMID:34217736 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
decreases activity |
ISO |
3-methylquercetin results in decreased activity of ABCC1 protein |
CTD |
PMID:15670588 |
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
ISO |
3-methylquercetin inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 mRNA]; 3-methylquercetin inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein] 3-methylquercetin inhibits the reaction [Carbon Tetrachloride results in increased expression of ACTA2 protein]; 3-methylquercetin inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 mRNA]; 3-methylquercetin inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein] |
CTD |
PMID:27151496 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Agt |
angiotensinogen |
multiple interactions |
EXP |
3-methylquercetin inhibits the reaction [AGT protein results in increased expression of NCF1 protein] |
CTD |
PMID:17374653 |
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions |
ISO |
3-methylquercetin inhibits the reaction [Benzo(a)pyrene results in increased activity of AHR protein] |
CTD |
PMID:19794518 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
decreases phosphorylation multiple interactions |
ISO EXP |
3-methylquercetin results in decreased phosphorylation of AKT1 protein 3-methylquercetin affects the reaction [Hydrogen Peroxide results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:12826665 PMID:19222219 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression |
ISO |
3-methylquercetin results in decreased expression of BCL2 mRNA; 3-methylquercetin results in decreased expression of BCL2 protein |
CTD |
PMID:22992727 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
decreases expression |
ISO |
3-methylquercetin results in decreased expression of BCL2L1 mRNA; 3-methylquercetin results in decreased expression of BCL2L1 protein |
CTD |
PMID:22992727 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479 Ensembl chr 1:141,253,523...141,303,479
|
|
G |
Casp3 |
caspase 3 |
decreases expression multiple interactions increases activity |
ISO EXP |
3-methylquercetin results in decreased expression of CASP3 protein 3-methylquercetin inhibits the reaction [Hydrogen Peroxide results in increased activity of CASP3 protein] 3-methylquercetin results in increased activity of CASP3 protein |
CTD |
PMID:12826665 PMID:19222219 PMID:22992727 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp9 |
caspase 9 |
decreases expression |
ISO |
3-methylquercetin results in decreased expression of CASP9 protein |
CTD |
PMID:22992727 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
3-methylquercetin inhibits the reaction [Hydrogen Peroxide results in decreased activity of CAT protein]; [quercetin 3-O-glucuronide co-treated with 3-methylquercetin co-treated with Quercetin] results in increased expression of CAT mRNA; [quercetin 3-O-glucuronide co-treated with 3-methylquercetin co-treated with Quercetin] results in increased expression of CAT protein |
CTD |
PMID:19222219 PMID:25716194 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
multiple interactions |
ISO |
[3-methylquercetin co-treated with Lipopolysaccharides] affects the expression of CCL3 mRNA |
CTD |
PMID:20579867 |
|
NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression |
ISO |
3-methylquercetin results in decreased expression of CCND1 mRNA; 3-methylquercetin results in decreased expression of CCND1 protein |
CTD |
PMID:22992727 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Cdh1 |
cadherin 1 |
increases expression |
ISO |
3-methylquercetin results in increased expression of CDH1 mRNA; 3-methylquercetin results in increased expression of CDH1 protein |
CTD |
PMID:37537191 |
|
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
multiple interactions |
ISO |
3-methylquercetin inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA] |
CTD |
PMID:27151496 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
3-methylquercetin inhibits the reaction [Benzo(a)pyrene results in increased activity of CYP1A1 protein]; [Quercetin co-treated with kaempferol co-treated with 3-methylquercetin co-treated with ginkgolide A co-treated with ginkgolide B co-treated with ginkgolide C co-treated with ginkgolide J co-treated with bilobalide] affects the activity of CYP1A1 protein; [Quercetin co-treated with kaempferol co-treated with 3-methylquercetin co-treated with ginkgolide A co-treated with ginkgolide B co-treated with ginkgolide C co-treated with ginkgolide J co-treated with bilobalide] inhibits the reaction [Benzo(a)pyrene results in increased activity of CYP1A1 protein]; [Quercetin co-treated with kaempferol co-treated with 3-methylquercetin co-treated with ginkgolide A co-treated with ginkgolide B co-treated with ginkgolide C co-treated with ginkgolide J co-treated with bilobalide] inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]; [Quercetin co-treated with kaempferol co-treated with 3-methylquercetin] affects the activity of CYP1A1 protein; [Quercetin co-treated with kaempferol co-treated with 3-methylquercetin] inhibits the reaction [Benzo(a)pyrene results in increased activity of CYP1A1 protein]; [Quercetin co-treated with kaempferol co-treated with 3-methylquercetin] inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein] |
CTD |
PMID:21329749 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
decreases expression |
ISO |
3-methylquercetin results in decreased expression of CYP1B1 mRNA |
CTD |
PMID:19794518 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
increases expression |
ISO |
3-methylquercetin results in increased expression of CYP3A4 mRNA |
CTD |
PMID:26238175 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Edn1 |
endothelin 1 |
multiple interactions |
EXP |
3-methylquercetin inhibits the reaction [EDN1 protein results in increased expression of NCF1 mRNA]; 3-methylquercetin inhibits the reaction [EDN1 protein results in increased expression of NCF1 protein] |
CTD |
PMID:18436224 |
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Esr1 |
estrogen receptor 1 |
affects binding |
ISO |
3-methylquercetin binds to ESR1 protein |
CTD |
PMID:14706564 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Esr2 |
estrogen receptor 2 |
affects binding |
ISO |
3-methylquercetin binds to ESR2 protein |
CTD |
PMID:14706564 |
|
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
multiple interactions increases expression |
ISO EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[3-methylquercetin results in increased activity of NFE2L2 protein] which results in increased expression of GCLC protein]; [3-methylquercetin affects the localization of and results in increased activity of NFE2L2 protein] which results in increased expression of GCLC protein; dorsomorphin inhibits the reaction [[3-methylquercetin results in increased activity of NFE2L2 protein] which results in increased expression of GCLC protein]; rottlerin inhibits the reaction [[3-methylquercetin results in increased activity of NFE2L2 protein] which results in increased expression of GCLC protein] [quercetin 3-O-glucuronide co-treated with 3-methylquercetin co-treated with Quercetin] results in increased expression of GCLC mRNA; [quercetin 3-O-glucuronide co-treated with 3-methylquercetin co-treated with Quercetin] results in increased expression of GCLC protein 3-methylquercetin results in increased expression of GCLC mRNA; 3-methylquercetin results in increased expression of GCLC protein |
CTD |
PMID:24211276 PMID:25716194 |
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
ISO |
3-methylquercetin inhibits the reaction [Carbon Tetrachloride results in increased expression of GPT protein] |
CTD |
PMID:27151496 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases expression |
ISO EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[3-methylquercetin results in increased activity of NFE2L2 protein] which results in increased expression of HMOX1 protein]; [3-methylquercetin affects the localization of and results in increased activity of NFE2L2 protein] which results in increased expression of HMOX1 protein; dorsomorphin inhibits the reaction [[3-methylquercetin results in increased activity of NFE2L2 protein] which results in increased expression of HMOX1 protein]; rottlerin inhibits the reaction [[3-methylquercetin results in increased activity of NFE2L2 protein] which results in increased expression of HMOX1 protein] [quercetin 3-O-glucuronide co-treated with 3-methylquercetin co-treated with Quercetin] results in increased expression of HMOX1 mRNA; [quercetin 3-O-glucuronide co-treated with 3-methylquercetin co-treated with Quercetin] results in increased expression of HMOX1 protein 3-methylquercetin results in increased expression of HMOX1 mRNA; 3-methylquercetin results in increased expression of HMOX1 protein 3-methylquercetin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of HMOX1 mRNA]; [3-methylquercetin results in increased activity of NFE2L2 protein] which results in increased expression of HMOX1 protein |
CTD |
PMID:24211276 PMID:24337631 PMID:25716194 PMID:27151496 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP ISO |
3-methylquercetin inhibits the reaction [Carrageenan results in increased expression of IL1B protein] 3-methylquercetin inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of IL1B protein]; 3-methylquercetin inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; [3-methylquercetin co-treated with Lipopolysaccharides] affects the expression of IL1B mRNA |
CTD |
PMID:20579867 PMID:23774260 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP ISO |
3-methylquercetin inhibits the reaction [Carrageenan results in increased expression of IL6 protein] 3-methylquercetin inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of IL6 protein]; 3-methylquercetin inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; [3-methylquercetin co-treated with Lipopolysaccharides] affects the expression of IL6 mRNA |
CTD |
PMID:20579867 PMID:23774260 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Mapk14 |
mitogen activated protein kinase 14 |
decreases expression |
ISO |
3-methylquercetin results in decreased expression of MAPK14 mRNA; 3-methylquercetin results in decreased expression of MAPK14 protein |
CTD |
PMID:36819991 PMID:37537191 |
|
NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
EXP |
3-methylquercetin inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:19222219 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mir155 |
microRNA 155 |
multiple interactions |
ISO |
3-methylquercetin inhibits the reaction [Lipopolysaccharides results in increased expression of MIR155 mRNA] |
CTD |
PMID:20579867 |
|
NCBI chr11:23,774,654...23,774,718
Ensembl chr11:23,774,654...23,774,718
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
decreases phosphorylation |
ISO |
3-methylquercetin results in decreased phosphorylation of MTOR protein |
CTD |
PMID:37537191 |
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Ncf1 |
neutrophil cytosolic factor 1 |
multiple interactions |
EXP |
3-methylquercetin inhibits the reaction [AGT protein results in increased expression of NCF1 protein]; 3-methylquercetin inhibits the reaction [EDN1 protein results in increased expression of NCF1 mRNA]; 3-methylquercetin inhibits the reaction [EDN1 protein results in increased expression of NCF1 protein] |
CTD |
PMID:17374653 PMID:18436224 |
|
NCBI chr12:22,485,382...22,494,647
Ensembl chr12:22,485,451...22,494,646
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
affects response to substance multiple interactions affects localization increases activity |
ISO |
NFE2L2 protein affects the susceptibility to 3-methylquercetin 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[3-methylquercetin results in increased activity of NFE2L2 protein] which results in increased expression of GCLC protein]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[3-methylquercetin results in increased activity of NFE2L2 protein] which results in increased expression of HMOX1 protein]; 3-methylquercetin affects the localization of and results in increased phosphorylation of and results in increased activity of NFE2L2 protein; [3-methylquercetin affects the localization of and results in increased activity of NFE2L2 protein] which results in increased abundance of Glutathione; [3-methylquercetin affects the localization of and results in increased activity of NFE2L2 protein] which results in increased expression of GCLC protein; [3-methylquercetin affects the localization of and results in increased activity of NFE2L2 protein] which results in increased expression of HMOX1 protein; [3-methylquercetin affects the localization of and results in increased activity of NFE2L2 protein] which results in increased expression of NQO1 mRNA; [3-methylquercetin affects the localization of and results in increased activity of NFE2L2 protein] which results in increased expression of SESN2 mRNA; dorsomorphin inhibits the reaction [[3-methylquercetin results in increased activity of NFE2L2 protein] which results in increased expression of GCLC protein]; dorsomorphin inhibits the reaction [[3-methylquercetin results in increased activity of NFE2L2 protein] which results in increased expression of HMOX1 protein]; NFE2L2 protein affects the reaction [3-methylquercetin inhibits the reaction [TGFB1 protein results in increased expression of SERPINE1 mRNA]]; NFE2L2 protein affects the reaction [3-methylquercetin inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD3 protein]]; rottlerin inhibits the reaction [[3-methylquercetin results in increased activity of NFE2L2 protein] which results in increased expression of GCLC protein]; rottlerin inhibits the reaction [[3-methylquercetin results in increased activity of NFE2L2 protein] which results in increased expression of HMOX1 protein] 3-methylquercetin affects the localization of NFE2L2 protein [3-methylquercetin results in increased activity of NFE2L2 protein] which results in increased expression of GCLC protein; [3-methylquercetin results in increased activity of NFE2L2 protein] which results in increased expression of HMOX1 protein; NFE2L2 protein affects the reaction [3-methylquercetin results in decreased susceptibility to tert-Butylhydroperoxide] |
CTD |
PMID:24211276 PMID:27151496 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
3-methylquercetin inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of and results in increased degradation of NFKBIA protein] |
CTD |
PMID:23774260 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
3-methylquercetin inhibits the reaction [[Lipopolysaccharides results in increased expression of and results in increased activity of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; 3-methylquercetin inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased activity of NOS2 protein]; 3-methylquercetin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; 3-methylquercetin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]; [3-methylquercetin co-treated with Lipopolysaccharides] affects the expression of NOS2 mRNA |
CTD |
PMID:16213685 PMID:18178435 PMID:18274639 PMID:20579867 PMID:23774260 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nos3 |
nitric oxide synthase 3 |
multiple interactions |
ISO |
3-methylquercetin inhibits the reaction [Lipids results in decreased expression of NOS3] |
CTD |
PMID:16891912 |
|
NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
ISO |
[3-methylquercetin affects the localization of and results in increased activity of NFE2L2 protein] which results in increased expression of NQO1 mRNA |
CTD |
PMID:24211276 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
multiple interactions increases activity |
ISO |
3-methylquercetin binds to and results in increased activity of NR1I2 protein 3-methylquercetin results in increased activity of NR1I2 protein |
CTD |
PMID:26238175 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Olr1 |
oxidized low density lipoprotein receptor 1 |
multiple interactions |
ISO |
3-methylquercetin inhibits the reaction [Lipids results in increased expression of OLR1] |
CTD |
PMID:16891912 |
|
NCBI chr 4:162,926,436...162,949,057
Ensembl chr 4:162,926,439...162,948,523
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage |
ISO |
3-methylquercetin results in increased cleavage of PARP1 protein |
CTD |
PMID:22992727 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pecam1 |
platelet and endothelial cell adhesion molecule 1 |
decreases expression |
ISO |
3-methylquercetin results in decreased expression of PECAM1 protein |
CTD |
PMID:22992727 |
|
NCBI chr10:91,590,521...91,652,279
Ensembl chr10:91,590,521...91,652,116
|
|
G |
Pon1 |
paraoxonase 1 |
increases expression |
ISO |
3-methylquercetin results in increased expression of PON1 mRNA |
CTD |
PMID:20228421 |
|
NCBI chr 4:33,294,737...33,325,759
Ensembl chr 4:33,294,722...33,321,360
|
|
G |
Pon2 |
paraoxonase 2 |
increases expression |
ISO |
3-methylquercetin results in increased expression of PON2 mRNA |
CTD |
PMID:19865538 |
|
NCBI chr 4:33,389,702...33,425,186
Ensembl chr 4:33,389,714...33,425,248
|
|
G |
Ppard |
peroxisome proliferator-activated receptor delta |
increases activity |
ISO |
3-methylquercetin results in increased activity of PPARD protein |
CTD |
PMID:22992727 |
|
NCBI chr20:6,298,785...6,363,970
Ensembl chr20:6,298,785...6,363,968
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions increases expression |
ISO |
2-chloro-5-nitrobenzanilide inhibits the reaction [3-methylquercetin results in increased activity of PPARG protein]; 3-methylquercetin binds to and results in increased activity of PPARG protein 3-methylquercetin results in increased expression of PPARG protein |
CTD |
PMID:22992727 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Prkcd |
protein kinase C, delta |
increases phosphorylation |
ISO |
3-methylquercetin results in increased phosphorylation of PRKCD protein |
CTD |
PMID:24211276 |
|
NCBI chr16:5,769,217...5,799,380
Ensembl chr16:5,769,215...5,799,352
|
|
G |
Ptges |
prostaglandin E synthase |
multiple interactions |
ISO |
3-methylquercetin inhibits the reaction [Lipopolysaccharides results in increased expression of PTGES mRNA] |
CTD |
PMID:21341175 |
|
NCBI chr 3:14,177,892...14,189,236
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions decreases activity |
ISO EXP |
3-methylquercetin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of PTGS2 mRNA]; 3-methylquercetin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of PTGS2 protein]; 3-methylquercetin inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]; 3-methylquercetin inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]; 3-methylquercetin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of PTGS2 protein]; Acetylcysteine promotes the reaction [3-methylquercetin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of PTGS2 protein]]; tin protoporphyrin IX inhibits the reaction [3-methylquercetin inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of PTGS2 protein]] 3-methylquercetin results in decreased activity of PTGS2 protein 3-methylquercetin inhibits the reaction [Carrageenan results in increased expression of PTGS2 protein] |
CTD |
PMID:15292928 PMID:21341175 PMID:24337631 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
3-methylquercetin inhibits the reaction [Lipopolysaccharides affects the localization of and results in increased activity of RELA protein]; 3-methylquercetin inhibits the reaction [Lipopolysaccharides affects the localization of RELA protein] |
CTD |
PMID:18274639 PMID:20579867 PMID:23774260 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Serpine1 |
serpin family E member 1 |
multiple interactions |
ISO |
3-methylquercetin inhibits the reaction [TGFB1 protein results in increased expression of SERPINE1 mRNA]; 3-methylquercetin inhibits the reaction [TGFB1 protein results in increased expression of SERPINE1 protein]; NFE2L2 protein affects the reaction [3-methylquercetin inhibits the reaction [TGFB1 protein results in increased expression of SERPINE1 mRNA]] 3-methylquercetin inhibits the reaction [Carbon Tetrachloride results in increased expression of SERPINE1 protein]; 3-methylquercetin inhibits the reaction [TGFB1 protein results in increased expression of SERPINE1 mRNA]; 3-methylquercetin inhibits the reaction [TGFB1 protein results in increased expression of SERPINE1 protein] |
CTD |
PMID:27151496 |
|
NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657
|
|
G |
Sesn2 |
sestrin 2 |
multiple interactions |
ISO |
[3-methylquercetin affects the localization of and results in increased activity of NFE2L2 protein] which results in increased expression of SESN2 mRNA |
CTD |
PMID:24211276 |
|
NCBI chr 5:144,702,287...144,721,241
Ensembl chr 5:144,701,530...144,721,260
|
|
G |
Smad2 |
SMAD family member 2 |
multiple interactions |
ISO |
3-methylquercetin inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD2 protein] |
CTD |
PMID:27151496 |
|
NCBI chr18:69,849,884...69,918,926
Ensembl chr18:69,850,377...69,912,323
|
|
G |
Smad3 |
SMAD family member 3 |
multiple interactions |
ISO |
3-methylquercetin inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD3 protein]; NFE2L2 protein affects the reaction [3-methylquercetin inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD3 protein]] |
CTD |
PMID:27151496 |
|
NCBI chr 8:64,126,829...64,236,960
Ensembl chr 8:64,110,039...64,236,960
|
|
G |
Tff1 |
trefoil factor 1 |
increases expression |
ISO |
3-methylquercetin results in increased expression of TFF1 mRNA |
CTD |
PMID:14706564 |
|
NCBI chr20:9,235,736...9,239,597
Ensembl chr20:9,235,736...9,239,597
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO |
3-methylquercetin inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 mRNA]; 3-methylquercetin inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein]; 3-methylquercetin inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA]; 3-methylquercetin inhibits the reaction [TGFB1 protein results in increased expression of SERPINE1 mRNA]; 3-methylquercetin inhibits the reaction [TGFB1 protein results in increased expression of SERPINE1 protein]; 3-methylquercetin inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD2 protein]; 3-methylquercetin inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD3 protein]; NFE2L2 protein affects the reaction [3-methylquercetin inhibits the reaction [TGFB1 protein results in increased expression of SERPINE1 mRNA]]; NFE2L2 protein affects the reaction [3-methylquercetin inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD3 protein]] |
CTD |
PMID:27151496 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP ISO |
3-methylquercetin inhibits the reaction [Carrageenan results in increased expression of TNF protein] 3-methylquercetin inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased secretion of TNF protein]; 3-methylquercetin inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; 3-methylquercetin inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein] |
CTD |
PMID:20579867 PMID:23774260 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tyr |
tyrosinase |
increases expression |
ISO |
3-methylquercetin results in increased expression of TYR protein |
CTD |
PMID:24853321 |
|
NCBI chr 1:141,115,036...141,210,207
Ensembl chr 1:141,115,036...141,210,207
|
|
G |
Tyrp1 |
tyrosinase-related protein 1 |
increases expression |
ISO |
3-methylquercetin results in increased expression of TYRP1 protein |
CTD |
PMID:24853321 |
|
NCBI chr 5:95,280,982...95,299,516
Ensembl chr 5:95,280,982...95,299,516
|
|
G |
Vim |
vimentin |
decreases expression |
ISO |
3-methylquercetin results in decreased expression of VIM mRNA; 3-methylquercetin results in decreased expression of VIM protein |
CTD |
PMID:37537191 |
|
NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187
|
|
|
G |
Abca13 |
ATP binding cassette subfamily A member 13 |
decreases expression |
ISO |
kojic acid results in decreased expression of ABCA13 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr14:83,873,397...84,376,138
Ensembl chr14:83,873,940...84,375,075
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in increased expression of ABCC2 mRNA; [Diethylnitrosamine co-treated with kojic acid] results in decreased expression of ABCC2 mRNA |
CTD |
PMID:18544905 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcc6 |
ATP binding cassette subfamily C member 6 |
multiple interactions |
ISO EXP |
[Diethylnitrosamine co-treated with kojic acid] results in increased expression of ABCC6 mRNA [Diethylnitrosamine co-treated with kojic acid] results in decreased expression of ABCC6 mRNA |
CTD |
PMID:17917374 PMID:18544905 |
|
NCBI chr 1:96,447,224...96,501,464
Ensembl chr 1:96,447,251...96,501,464
|
|
G |
Abcc9 |
ATP binding cassette subfamily C member 9 |
multiple interactions |
ISO |
[Diethylnitrosamine co-treated with kojic acid] results in increased expression of ABCC9 mRNA |
CTD |
PMID:17917374 |
|
NCBI chr 4:175,531,854...175,655,849
Ensembl chr 4:175,532,547...175,655,356
|
|
G |
Abcd1 |
ATP binding cassette subfamily D member 1 |
multiple interactions |
ISO |
[Diethylnitrosamine co-treated with kojic acid] results in increased expression of ABCD1 mRNA |
CTD |
PMID:17917374 |
|
NCBI chr X:151,428,334...151,450,115
Ensembl chr X:151,428,578...151,450,115
|
|
G |
Abcf2 |
ATP binding cassette subfamily F member 2 |
multiple interactions |
ISO |
[Diethylnitrosamine co-treated with kojic acid] results in increased expression of ABCF2 mRNA |
CTD |
PMID:17917374 |
|
NCBI chr 4:10,594,802...10,607,620
Ensembl chr 4:10,594,907...10,607,606
|
|
G |
Abhd1 |
abhydrolase domain containing 1 |
multiple interactions |
ISO |
[Diethylnitrosamine co-treated with kojic acid] results in decreased expression of ABHD1 mRNA |
CTD |
PMID:17917374 |
|
NCBI chr 6:25,422,526...25,427,514
Ensembl chr 6:25,422,526...25,427,514
|
|
G |
Acer3 |
alkaline ceramidase 3 |
increases expression |
ISO |
kojic acid results in increased expression of ACER3 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 1:152,504,180...152,606,596
Ensembl chr 1:152,504,186...152,606,591
|
|
G |
Acmsd |
aminocarboxymuconate semialdehyde decarboxylase |
decreases expression |
ISO |
kojic acid results in decreased expression of ACMSD mRNA |
CTD |
PMID:16595896 |
|
NCBI chr13:39,200,412...39,245,954
Ensembl chr13:39,200,314...39,245,209
|
|
G |
Acvrl1 |
activin A receptor like type 1 |
decreases expression |
ISO |
kojic acid results in decreased expression of ACVRL1 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 7:132,239,200...132,256,592
Ensembl chr 7:132,239,729...132,256,591
|
|
G |
Adrb3 |
adrenoceptor beta 3 |
decreases expression |
ISO |
kojic acid results in decreased expression of ADRB3 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr16:64,839,820...64,844,552
Ensembl chr16:64,841,788...64,844,552
|
|
G |
Agap3 |
ArfGAP with GTPase domain, ankyrin repeat and PH domain 3 |
increases expression |
ISO |
kojic acid results in increased expression of AGAP3 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 4:10,674,746...10,724,848
Ensembl chr 4:10,674,064...10,725,244
|
|
G |
Agbl4 |
AGBL carboxypeptidase 4 |
decreases expression |
ISO |
kojic acid results in decreased expression of AGBL4 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 5:125,254,963...126,534,367
Ensembl chr 5:125,254,956...126,534,367
|
|
G |
Ahnak |
AHNAK nucleoprotein |
decreases expression |
ISO |
kojic acid results in decreased expression of AHNAK mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 1:205,882,225...205,970,934
Ensembl chr 1:205,882,273...205,970,926
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
decreases expression |
ISO |
kojic acid results in decreased expression of AKT1 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Alpi |
alkaline phosphatase, intestinal |
decreases expression |
ISO |
kojic acid results in decreased expression of ALPI mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 9:87,773,411...87,776,877
Ensembl chr 9:87,773,411...87,776,877
|
|
G |
Amtn |
amelotin |
decreases expression |
ISO |
kojic acid results in decreased expression of AMTN mRNA |
CTD |
PMID:16595896 |
|
NCBI chr14:19,648,624...19,661,181
Ensembl chr14:19,648,625...19,661,181
|
|
G |
Anxa1 |
annexin A1 |
decreases expression |
ISO |
kojic acid results in decreased expression of ANXA1 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 1:217,861,175...217,877,205
Ensembl chr 1:217,861,175...217,877,343
|
|
G |
Anxa5 |
annexin A5 |
multiple interactions |
ISO |
[Diethylnitrosamine co-treated with kojic acid co-treated with Ascorbic Acid] results in increased expression of ANXA5 mRNA |
CTD |
PMID:17917374 |
|
NCBI chr 2:119,314,007...119,344,703
Ensembl chr 2:119,314,007...119,353,369
|
|
G |
Ap1s1 |
adaptor related protein complex 1 subunit sigma 1 |
decreases expression |
ISO |
kojic acid results in decreased expression of AP1S1 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr12:19,625,267...19,635,792
Ensembl chr12:19,625,332...19,756,713
|
|
G |
Apobec1 |
apolipoprotein B mRNA editing enzyme catalytic subunit 1 |
decreases expression |
ISO |
kojic acid results in decreased expression of APOBEC1 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 4:155,800,030...155,828,515
Ensembl chr 4:155,800,887...155,827,390
|
|
G |
App |
amyloid beta precursor protein |
increases expression |
ISO |
kojic acid results in increased expression of APP mRNA |
CTD |
PMID:16595896 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Aptx |
aprataxin |
decreases expression |
ISO |
kojic acid results in decreased expression of APTX mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 5:55,798,896...55,822,963
Ensembl chr 5:55,800,248...55,822,855
|
|
G |
Aqp1 |
aquaporin 1 |
increases expression |
ISO |
kojic acid results in increased expression of AQP1 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 4:84,482,512...84,494,690
Ensembl chr 4:84,482,512...84,494,690
|
|
G |
Arfip2 |
ARF interacting protein 2 |
decreases expression |
ISO |
kojic acid results in decreased expression of ARFIP2 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 1:159,974,255...159,980,398
Ensembl chr 1:159,974,201...159,980,336
|
|
G |
Arhgef16 |
Rho guanine nucleotide exchange factor 16 |
decreases expression |
ISO |
kojic acid results in decreased expression of ARHGEF16 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 5:164,843,656...164,866,212
Ensembl chr 5:164,844,161...164,866,212
|
|
G |
Arl6ip5 |
ARF like GTPase 6 interacting protein 5 |
increases expression |
ISO |
kojic acid results in increased expression of ARL6IP5 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 4:129,810,650...129,838,628
Ensembl chr 4:129,810,645...129,838,608
|
|
G |
Asnsd1 |
asparagine synthetase domain containing 1 |
decreases expression |
ISO |
kojic acid results in decreased expression of ASNSD1 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 9:48,126,808...48,139,073
Ensembl chr 9:48,126,808...48,139,073
|
|
G |
Atf6b |
activating transcription factor 6 beta |
decreases expression |
ISO |
kojic acid results in decreased expression of ATF6B mRNA |
CTD |
PMID:16595896 |
|
NCBI chr20:4,090,921...4,098,920
Ensembl chr20:4,090,921...4,098,894
|
|
G |
Atm |
ATM serine/threonine kinase |
multiple interactions |
ISO |
[Diethylnitrosamine co-treated with kojic acid co-treated with Ascorbic Acid] results in increased expression of ATM mRNA |
CTD |
PMID:17917374 |
|
NCBI chr 8:53,828,741...53,932,773
Ensembl chr 8:53,831,093...53,932,437
|
|
G |
B4galnt4 |
beta-1,4-N-acetyl-galactosaminyl transferase 4 |
decreases expression |
ISO |
kojic acid results in decreased expression of B4GALNT4 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 1:196,171,394...196,182,294
Ensembl chr 1:196,171,394...196,182,294
|
|
G |
Bag5 |
BAG cochaperone 5 |
decreases expression |
ISO |
kojic acid results in decreased expression of BAG5 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 6:130,768,467...130,772,122
Ensembl chr 6:130,768,141...130,772,970
|
|
G |
Bcl2a1 |
BCL2-related protein A1 |
increases expression |
ISO |
kojic acid results in increased expression of BCL2A1 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 8:89,716,914...89,724,998
Ensembl chr 8:89,716,914...89,724,998
|
|
G |
Bcl2l2 |
Bcl2-like 2 |
multiple interactions |
ISO |
[Diethylnitrosamine co-treated with kojic acid co-treated with Ascorbic Acid] results in increased expression of BCL2L2 mRNA |
CTD |
PMID:17917374 |
|
NCBI chr15:28,346,449...28,361,627
Ensembl chr15:28,356,807...28,361,624
|
|
G |
Birc2 |
baculoviral IAP repeat-containing 2 |
decreases expression |
ISO |
kojic acid results in decreased expression of BIRC2 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 8:4,968,856...4,989,325
Ensembl chr 8:4,968,842...4,988,732
|
|
G |
Bmp5 |
bone morphogenetic protein 5 |
decreases expression |
ISO |
kojic acid results in decreased expression of BMP5 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 8:76,517,164...76,639,925
Ensembl chr 8:76,517,164...76,639,925
|
|
G |
Brsk1 |
BR serine/threonine kinase 1 |
decreases expression |
ISO |
kojic acid results in decreased expression of BRSK1 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 1:69,134,166...69,159,947
Ensembl chr 1:69,134,565...69,160,365
|
|
G |
Bst2 |
bone marrow stromal cell antigen 2 |
decreases expression |
ISO |
kojic acid results in decreased expression of BST2 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr16:18,216,605...18,220,979
Ensembl chr16:18,217,407...18,220,979
|
|
G |
C2h1orf54 |
similar to human chromosome 1 open reading frame 54 |
increases expression |
ISO |
kojic acid results in increased expression of C1ORF54 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 2:183,424,989...183,434,713
Ensembl chr 2:183,424,984...183,435,089
|
|
G |
C5h1orf87 |
similar to human chromosome 1 open reading frame 87 |
decreases expression |
ISO |
kojic acid results in decreased expression of C1ORF87 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 5:111,342,381...111,411,576
Ensembl chr 5:111,342,387...111,411,590
|
|
G |
Cab39l |
calcium binding protein 39-like |
increases expression |
ISO |
kojic acid results in increased expression of CAB39L mRNA |
CTD |
PMID:16595896 |
|
NCBI chr15:33,606,588...33,710,518
Ensembl chr15:33,606,694...33,743,545
|
|
G |
Calr |
calreticulin |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of CALR mRNA |
CTD |
PMID:18544905 |
|
NCBI chr19:23,308,525...23,313,420
Ensembl chr19:23,308,351...23,313,414
|
|
G |
Car13 |
carbonic anhydrase 13 |
increases expression |
ISO |
kojic acid results in increased expression of CAR13 mRNA |
CTD |
PMID:19000923 |
|
NCBI chr 2:86,928,401...86,959,525
Ensembl chr 2:86,928,383...86,959,525
|
|
G |
Car14 |
carbonic anhydrase 14 |
increases expression |
ISO |
kojic acid results in increased expression of CA14 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 2:183,442,263...183,449,231
Ensembl chr 2:183,441,667...183,449,693
|
|
G |
Casp4 |
caspase 4 |
multiple interactions |
EXP |
[kojic acid co-treated with Diethylnitrosamine] results in increased expression of CASP4 mRNA; Ascorbic Acid inhibits the reaction [[kojic acid co-treated with Diethylnitrosamine] results in increased expression of CASP4 mRNA] |
CTD |
PMID:18544905 |
|
NCBI chr 8:2,599,017...2,635,097
Ensembl chr 8:2,598,876...2,635,092
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
EXP |
[Ascorbic Acid co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of CASP8 mRNA |
CTD |
PMID:18544905 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of CAT mRNA |
CTD |
PMID:18544905 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccar1 |
cell division cycle and apoptosis regulator 1 |
increases expression |
ISO |
kojic acid results in increased expression of CCAR1 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr20:30,685,916...30,728,531
Ensembl chr20:30,685,916...30,728,526
|
|
G |
Ccdc50 |
coiled-coil domain containing 50 |
increases expression |
ISO |
kojic acid results in increased expression of CCDC50 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr11:73,332,798...73,395,333
Ensembl chr11:73,334,248...73,395,150
|
|
G |
Ccl21 |
C-C motif chemokine ligand 21 |
multiple interactions |
ISO |
[Diethylnitrosamine co-treated with kojic acid co-treated with Ascorbic Acid] results in increased expression of CCL21A mRNA |
CTD |
PMID:17917374 |
|
NCBI chr 5:56,980,557...56,981,661
Ensembl chr 5:56,980,558...56,981,686
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
multiple interactions |
ISO |
[Diethylnitrosamine co-treated with kojic acid co-treated with Ascorbic Acid] results in increased expression of CCL3 mRNA |
CTD |
PMID:17917374 |
|
NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
|
|
G |
Ccnb1 |
cyclin B1 |
increases expression |
ISO |
kojic acid results in increased expression of CCNB1 mRNA |
CTD |
PMID:19000923 |
|
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
|
|
G |
Ccnc |
cyclin C |
multiple interactions |
ISO |
[Diethylnitrosamine co-treated with kojic acid co-treated with Ascorbic Acid] results in increased expression of CCNC mRNA |
CTD |
PMID:17917374 |
|
NCBI chr 5:35,266,828...35,284,943
Ensembl chr 5:35,266,823...35,296,584
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions |
EXP ISO |
[Diethylnitrosamine co-treated with kojic acid] results in decreased expression of CCND1 mRNA [Diethylnitrosamine co-treated with kojic acid co-treated with Ascorbic Acid] results in increased expression of CCND1 mRNA |
CTD |
PMID:17917374 PMID:18544905 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccng1 |
cyclin G1 |
multiple interactions |
EXP ISO |
[Ascorbic Acid co-treated with kojic acid co-treated with Diethylnitrosamine] results in increased expression of CCNG1 mRNA [Diethylnitrosamine co-treated with kojic acid co-treated with Ascorbic Acid] results in increased expression of CCNG1 mRNA |
CTD |
PMID:17917374 PMID:18544905 |
|
NCBI chr10:25,176,231...25,182,604
Ensembl chr10:25,176,234...25,181,641
|
|
G |
Ccpg1 |
cell cycle progression 1 |
decreases expression |
ISO |
kojic acid results in decreased expression of CCPG1 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 8:73,719,960...73,752,437
Ensembl chr 8:73,719,955...73,752,430
|
|
G |
Ccr4 |
C-C motif chemokine receptor 4 |
decreases expression |
ISO |
kojic acid results in decreased expression of CCR4 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 8:114,176,291...114,182,033
Ensembl chr 8:114,176,974...114,178,056
|
|
G |
Cd22 |
CD22 molecule |
decreases expression |
ISO |
kojic acid results in decreased expression of CD22 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 1:86,116,376...86,132,782
Ensembl chr 1:86,117,459...86,132,322
|
|
G |
Cd274 |
CD274 molecule |
increases expression |
ISO |
kojic acid results in increased expression of CD274 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 1:227,116,674...227,137,379
Ensembl chr 1:227,116,649...227,134,450
|
|
G |
Cd3g |
CD3 gamma subunit of T-cell receptor complex |
decreases expression |
ISO |
kojic acid results in decreased expression of CD3G mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 8:45,280,797...45,287,271
Ensembl chr 8:45,281,204...45,287,147
|
|
G |
Cdin1 |
CDAN1 interacting nuclease 1 |
increases expression |
ISO |
kojic acid results in increased expression of CDIN1 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 3:102,441,553...102,646,935
Ensembl chr 3:102,441,704...102,646,682
|
|
G |
Cdk10 |
cyclin-dependent kinase 10 |
decreases expression |
ISO |
kojic acid results in decreased expression of CDK10 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr19:51,260,012...51,273,009
Ensembl chr19:51,261,356...51,269,078
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions |
ISO EXP |
[Diethylnitrosamine co-treated with kojic acid co-treated with Ascorbic Acid] results in increased expression of CDKN1A mRNA [Diethylnitrosamine co-treated with kojic acid] results in increased expression of CDKN1A mRNA |
CTD |
PMID:17917374 PMID:18544905 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
multiple interactions |
EXP |
[Ascorbic Acid co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of CDKN1B mRNA; [Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of CDKN1B mRNA |
CTD |
PMID:18544905 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Ceacam1 |
CEA cell adhesion molecule 1 |
decreases expression |
ISO |
kojic acid results in decreased expression of CEACAM1 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 1:81,043,595...81,060,050
Ensembl chr 1:81,043,595...81,059,992
|
|
G |
Cebpd |
CCAAT/enhancer binding protein delta |
increases expression |
ISO |
kojic acid results in increased expression of CEBPD mRNA |
CTD |
PMID:16595896 |
|
NCBI chr11:84,764,670...84,765,808
Ensembl chr11:84,764,565...84,765,829
|
|
G |
Cenpq |
centromere protein Q |
decreases expression |
ISO |
kojic acid results in decreased expression of CENPQ mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 9:19,957,122...19,972,807
Ensembl chr 9:19,957,048...19,972,789
|
|
G |
Cep192 |
centrosomal protein 192 |
increases expression |
ISO |
kojic acid results in increased expression of CEP192 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr18:61,373,937...61,458,405
Ensembl chr18:61,332,158...61,458,379
|
|
G |
Cep72 |
centrosomal protein 72 |
increases expression |
ISO |
kojic acid results in increased expression of CEP72 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 1:29,225,312...29,255,294
Ensembl chr 1:29,225,361...29,255,271
|
|
G |
Ces1d |
carboxylesterase 1D |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with kojic acid] results in increased expression of CES1 mRNA |
CTD |
PMID:18544905 |
|
NCBI chr19:13,873,490...13,912,035
Ensembl chr19:13,796,623...13,912,035
|
|
G |
Chek2 |
checkpoint kinase 2 |
multiple interactions |
EXP |
[kojic acid co-treated with Diethylnitrosamine] results in increased expression of CHEK2 mRNA; Ascorbic Acid inhibits the reaction [[kojic acid co-treated with Diethylnitrosamine] results in increased expression of CHEK2 mRNA] |
CTD |
PMID:18544905 |
|
NCBI chr12:45,788,823...45,821,382
Ensembl chr12:45,788,827...45,821,286
|
|
G |
Chst4 |
carbohydrate sulfotransferase 4 |
multiple interactions |
ISO |
[Diethylnitrosamine co-treated with kojic acid] results in decreased expression of CHST4 mRNA |
CTD |
PMID:17917374 |
|
NCBI chr19:37,993,471...38,002,123
Ensembl chr19:37,991,417...38,003,608
|
|
G |
Cibar1 |
CBY1 interacting BAR domain containing 1 |
increases expression |
ISO |
kojic acid results in increased expression of CIBAR1 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 5:25,613,993...25,632,440
Ensembl chr 5:25,614,033...25,632,489
|
|
G |
Cldn3 |
claudin 3 |
decreases expression |
ISO |
kojic acid results in decreased expression of CLDN3 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr12:21,708,538...21,710,010
Ensembl chr12:21,708,398...21,711,001
|
|
G |
Cldnd2 |
claudin domain containing 2 |
decreases expression |
ISO |
kojic acid results in decreased expression of CLDND2 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 1:93,848,533...93,851,693
Ensembl chr 1:93,848,533...93,851,217
|
|
G |
Clec4b2 |
C-type lectin domain family 4, member B2 |
decreases expression |
ISO |
kojic acid results in decreased expression of CLEC4C mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 4:156,462,742...156,486,240
Ensembl chr 4:156,462,742...156,486,240
|
|
G |
Clmp |
CXADR-like membrane protein |
decreases expression |
ISO |
kojic acid results in decreased expression of CLMP mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 8:41,060,527...41,168,841
Ensembl chr 8:41,060,799...41,168,838
|
|
G |
Clu |
clusterin |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of CLU mRNA |
CTD |
PMID:18544905 |
|
NCBI chr15:40,161,068...40,200,315
Ensembl chr15:40,174,617...40,200,315
|
|
G |
Cnih1 |
cornichon family member 1 |
increases expression |
ISO |
kojic acid results in increased expression of CNIH1 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr15:20,037,885...20,049,857
Ensembl chr15:20,037,885...20,049,761
|
|
G |
Cnksr2 |
connector enhancer of kinase suppressor of Ras 2 |
decreases expression |
ISO |
kojic acid results in decreased expression of CNKSR2 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr X:36,908,135...37,148,337
Ensembl chr X:36,907,850...37,150,555
|
|
G |
Col17a1 |
collagen type XVII alpha 1 chain |
decreases expression |
ISO |
kojic acid results in decreased expression of COL17A1 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 1:246,530,589...246,577,559
Ensembl chr 1:246,531,367...246,577,632
|
|
G |
Col24a1 |
collagen type XXIV alpha 1 chain |
decreases expression |
ISO |
kojic acid results in decreased expression of COL24A1 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 2:234,212,256...234,469,445
Ensembl chr 2:234,212,324...234,469,441
|
|
G |
Colq |
collagen like tail subunit of asymmetric acetylcholinesterase |
increases expression |
ISO |
kojic acid results in increased expression of COLQ mRNA |
CTD |
PMID:16595896 |
|
NCBI chr16:6,731,850...6,824,973
Ensembl chr16:6,731,858...6,787,107
|
|
G |
Comt |
catechol-O-methyltransferase |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of COMT mRNA |
CTD |
PMID:18544905 |
|
NCBI chr11:82,568,052...82,587,642
Ensembl chr11:82,568,025...82,587,642
|
|
G |
Cops2 |
COP9 signalosome subunit 2 |
decreases expression |
ISO |
kojic acid results in decreased expression of COPS2 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 3:113,084,174...113,110,090
Ensembl chr 3:113,084,176...113,109,947
|
|
G |
Coq10a |
coenzyme Q10A |
increases expression |
ISO |
kojic acid results in increased expression of COQ10A mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 7:792,089...798,392
Ensembl chr 7:792,089...800,161
|
|
G |
Coq8a |
coenzyme Q8A |
increases expression |
ISO |
kojic acid results in increased expression of COQ8A mRNA |
CTD |
PMID:16595896 |
|
NCBI chr13:91,904,731...91,933,588
Ensembl chr13:91,904,739...91,931,431
|
|
G |
Cpb1 |
carboxypeptidase B1 |
decreases expression |
ISO |
kojic acid results in decreased expression of CPB1 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 2:102,755,241...102,785,628
Ensembl chr 2:102,755,241...102,785,628
|
|
G |
Cpe |
carboxypeptidase E |
increases expression |
ISO |
kojic acid results in increased expression of CPE mRNA |
CTD |
PMID:16595896 |
|
NCBI chr16:25,030,276...25,142,231
Ensembl chr16:25,030,276...25,142,233
|
|
G |
Cpne5 |
copine 5 |
increases expression |
ISO |
kojic acid results in increased expression of CPNE5 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr20:7,206,742...7,289,309
Ensembl chr20:7,206,742...7,288,883
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
decreases phosphorylation |
ISO |
kojic acid results in decreased phosphorylation of CREB1 protein |
CTD |
PMID:27586645 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Cse1l |
chromosome segregation 1 like |
decreases expression |
ISO |
kojic acid results in decreased expression of CSE1L mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 3:155,641,104...155,678,866
Ensembl chr 3:155,641,166...155,678,865
|
|
G |
Ctnnal1 |
catenin alpha-like 1 |
decreases expression |
ISO |
kojic acid results in decreased expression of CTNNAL1 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 5:71,514,340...71,569,431
Ensembl chr 5:71,514,340...71,569,431
|
|
G |
Ctsz |
cathepsin Z |
increases expression |
ISO |
kojic acid results in increased expression of CTSZ mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 3:163,224,875...163,235,645
Ensembl chr 3:163,224,875...163,235,645
|
|
G |
Cyb5r3 |
cytochrome b5 reductase 3 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of CYB5R3 mRNA; [Diethylnitrosamine co-treated with kojic acid] results in increased expression of CYB5R3 mRNA |
CTD |
PMID:18544905 |
|
NCBI chr 7:114,306,686...114,324,247
Ensembl chr 7:114,306,685...114,324,298
|
|
G |
Cyp26b1 |
cytochrome P450, family 26, subfamily b, polypeptide 1 |
increases expression |
ISO |
kojic acid results in increased expression of CYP26B1 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 4:117,041,808...117,058,628
Ensembl chr 4:117,041,808...117,058,628
|
|
G |
Cyp2b15 |
cytochrome P450, family 2, subfamily b, polypeptide 15 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of CYP2B15 mRNA; [Diethylnitrosamine co-treated with kojic acid] results in increased expression of CYP2B15 mRNA |
CTD |
PMID:18544905 |
|
NCBI chr 1:82,094,188...82,106,492
Ensembl chr 1:82,094,180...82,106,492
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
multiple interactions |
ISO |
[Diethylnitrosamine co-treated with kojic acid co-treated with Ascorbic Acid] results in increased expression of CYP2B10 mRNA |
CTD |
PMID:17917374 |
|
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of CYP2C mRNA |
CTD |
PMID:18544905 |
|
NCBI chr 1:236,762,719...236,799,069
Ensembl chr 1:236,762,842...236,799,066
|
|
G |
Cyp2c13 |
cytochrome P450, family 2, subfamily c, polypeptide 13 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of CYP2C13 mRNA |
CTD |
PMID:18544905 |
|
NCBI chr 1:238,786,764...238,867,195
Ensembl chr 1:238,786,765...238,867,191
|
|
G |
Cyp2c7 |
cytochrome P450, family 2, subfamily c, polypeptide 7 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of CYP2C7 mRNA |
CTD |
PMID:18544905 |
|
NCBI chr 1:237,332,641...237,388,714
Ensembl chr 1:237,332,659...237,388,709
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of CYP2D22 mRNA; [Diethylnitrosamine co-treated with kojic acid] results in increased expression of CYP2D22 mRNA |
CTD |
PMID:18544905 |
|
NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of CYP2E1 mRNA |
CTD |
PMID:18544905 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cyp2f4 |
cytochrome P450, family 2, subfamily f, polypeptide 4 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of CYP2F2 mRNA; [Diethylnitrosamine co-treated with kojic acid] results in increased expression of CYP2F2 mRNA |
CTD |
PMID:18544905 |
|
NCBI chr 1:82,416,107...82,429,897
Ensembl chr 1:82,416,130...82,429,896
|
|
G |
Cyp4a1 |
cytochrome P450, family 4, subfamily a, polypeptide 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of CYP4A22 mRNA; [Diethylnitrosamine co-treated with kojic acid] results in increased expression of CYP4A22 mRNA |
CTD |
PMID:18544905 |
|
NCBI chr 5:129,123,323...129,137,464
Ensembl chr 5:129,123,336...129,137,464
|
|
G |
Cyp4b1 |
cytochrome P450, family 4, subfamily b, polypeptide 1 |
multiple interactions |
ISO EXP |
[Diethylnitrosamine co-treated with kojic acid] results in decreased expression of CYP4B1 mRNA [Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of CYP4B1 mRNA |
CTD |
PMID:17917374 PMID:18544905 |
|
NCBI chr 5:129,139,019...129,176,860
Ensembl chr 5:129,139,038...129,156,348
|
|
G |
Cyp4f4 |
cytochrome P450, family 4, subfamily f, polypeptide 4 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of CYP4F2 mRNA |
CTD |
PMID:18544905 |
|
NCBI chr 7:11,717,208...11,733,507
Ensembl chr 7:11,717,208...11,733,506
|
|
G |
Cyp7a1 |
cytochrome P450 family 7 subfamily A member 1 |
multiple interactions |
ISO |
[Diethylnitrosamine co-treated with kojic acid co-treated with Ascorbic Acid] results in increased expression of CYP7A1 mRNA; [Diethylnitrosamine co-treated with kojic acid] results in increased expression of CYP7A1 mRNA |
CTD |
PMID:17917374 |
|
NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688
|
|
G |
Cyp8b1 |
cytochrome P450 family 8 subfamily B member 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of CYP8B1 mRNA |
CTD |
PMID:18544905 |
|
NCBI chr 8:121,578,123...121,580,093
Ensembl chr 8:121,557,062...121,580,166
|
|
G |
Cyth3 |
cytohesin 3 |
increases expression |
ISO |
kojic acid results in increased expression of CYTH3 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr12:10,840,137...10,933,792
Ensembl chr12:10,840,157...10,933,812
|
|
G |
Cytip |
cytohesin 1 interacting protein |
increases expression |
ISO |
kojic acid results in increased expression of CYTIP mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 3:42,698,058...42,774,955
Ensembl chr 3:42,698,768...42,725,993
|
|
G |
Dagla |
diacylglycerol lipase, alpha |
increases expression |
ISO |
kojic acid results in increased expression of DAGLA mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 1:206,890,635...206,947,332
Ensembl chr 1:206,890,638...206,947,232
|
|
G |
Dazap2 |
DAZ associated protein 2 |
increases expression |
ISO |
kojic acid results in increased expression of DAZAP2 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 7:131,714,749...131,720,266
Ensembl chr 7:131,714,745...131,720,265
|
|
G |
Dcaf13 |
DDB1 and CUL4 associated factor 13 |
decreases expression |
ISO |
kojic acid results in decreased expression of DCAF13 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 7:70,160,983...70,196,142
Ensembl chr 7:70,160,941...70,196,142
|
|
G |
Dct |
dopachrome tautomerase |
decreases expression |
ISO |
kojic acid results in decreased expression of DCT protein |
CTD |
PMID:27586645 |
|
NCBI chr15:95,062,006...95,100,863
Ensembl chr15:95,062,003...95,100,836
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions |
EXP |
[Ascorbic Acid co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of DDIT3 mRNA |
CTD |
PMID:18544905 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Dek |
DEK proto-oncogene |
decreases expression |
ISO |
kojic acid results in decreased expression of DEK mRNA |
CTD |
PMID:16595896 |
|
NCBI chr17:17,580,804...17,602,825
Ensembl chr17:17,580,843...17,602,808
|
|
G |
Dlgap4 |
DLG associated protein 4 |
increases expression |
ISO |
kojic acid results in increased expression of DLGAP4 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 3:145,124,189...145,271,791
Ensembl chr 3:145,175,479...145,270,490
|
|
G |
Dlx1 |
distal-less homeobox 1 |
decreases expression |
ISO |
kojic acid results in decreased expression of DLX1 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 3:56,356,190...56,360,780
Ensembl chr 3:56,356,190...56,360,780
|
|
G |
Dmxl1 |
Dmx-like 1 |
decreases expression |
ISO |
kojic acid results in decreased expression of DMXL1 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr18:42,993,292...43,163,457
Ensembl chr18:42,993,340...43,163,456
|
|
G |
Dnaja1 |
DnaJ heat shock protein family (Hsp40) member A1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of DNAJA1 mRNA |
CTD |
PMID:18544905 |
|
NCBI chr 5:55,842,414...55,853,326
Ensembl chr 5:55,842,426...55,853,967
|
|
G |
Dnaja2 |
DnaJ heat shock protein family (Hsp40) member A2 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of DNAJA2 mRNA; [Diethylnitrosamine co-treated with kojic acid] results in increased expression of DNAJA2 mRNA |
CTD |
PMID:18544905 |
|
NCBI chr19:21,497,792...21,516,904
Ensembl chr19:21,497,729...21,516,901
|
|
G |
Dnttip2 |
deoxynucleotidyltransferase, terminal, interacting protein 2 |
decreases expression |
ISO |
kojic acid results in decreased expression of DNTTIP2 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 2:210,374,321...210,386,366
Ensembl chr 2:210,374,289...210,385,581
|
|
G |
Dock4 |
dedicator of cytokinesis 4 |
increases expression |
ISO |
kojic acid results in increased expression of DOCK4 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 6:57,512,929...57,902,597
Ensembl chr 6:57,512,908...57,901,855
|
|
G |
Dok4 |
docking protein 4 |
decreases expression |
ISO |
kojic acid results in decreased expression of DOK4 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr19:10,146,520...10,157,187
Ensembl chr19:10,146,474...10,158,203
|
|
G |
Dpyd |
dihydropyrimidine dehydrogenase |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with kojic acid] results in increased expression of DPYD mRNA |
CTD |
PMID:18544905 |
|
NCBI chr 2:206,609,043...207,474,982
Ensembl chr 2:206,609,122...207,474,982
|
|
G |
Dspp |
dentin sialophosphoprotein |
decreases expression |
ISO |
kojic acid results in decreased expression of DSPP mRNA |
CTD |
PMID:16595896 |
|
NCBI chr14:5,565,562...5,571,669
Ensembl chr14:5,565,629...5,571,672
|
|
G |
Dstn |
destrin, actin depolymerizing factor |
increases expression |
ISO |
kojic acid results in increased expression of DSTN mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 3:131,284,647...131,311,361
Ensembl chr 3:131,284,648...131,311,379
|
|
G |
Dynlt3 |
dynein light chain Tctex-type 3 |
decreases expression |
ISO |
kojic acid results in decreased expression of DYNLT3 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr X:13,327,933...13,337,139
Ensembl chr X:13,327,892...13,337,139
|
|
G |
E2f3 |
E2F transcription factor 3 |
increases expression |
ISO |
kojic acid results in increased expression of E2F3 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr17:34,601,756...34,679,139
Ensembl chr17:34,601,830...34,676,253
|
|
G |
E2f8 |
E2F transcription factor 8 |
increases expression |
ISO |
kojic acid results in increased expression of E2F8 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 1:98,565,717...98,584,265
Ensembl chr 1:98,565,717...98,584,098
|
|
G |
Efna3 |
ephrin A3 |
decreases expression |
ISO |
kojic acid results in decreased expression of EFNA3 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 2:174,729,192...174,738,111
Ensembl chr 2:174,729,764...174,738,736
|
|
G |
Egr1 |
early growth response 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in increased expression of EGR1 mRNA |
CTD |
PMID:18544905 |
|
NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Eif4e |
eukaryotic translation initiation factor 4E |
decreases expression |
ISO |
kojic acid results in decreased expression of EIF4E mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 2:227,066,519...227,099,261
Ensembl chr 2:227,066,673...227,098,683
|
|
G |
Eif5a2 |
eukaryotic translation initiation factor 5A2 |
increases expression |
ISO |
kojic acid results in increased expression of EIF5A2 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 2:111,728,587...111,746,087
Ensembl chr 2:111,729,323...111,746,087
|
|
G |
Elane |
elastase, neutrophil expressed |
decreases expression |
ISO |
kojic acid results in decreased expression of ELANE mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 7:9,817,251...9,819,174
Ensembl chr 7:9,817,252...9,819,100
|
|
G |
Ep300 |
E1A binding protein p300 |
increases expression |
ISO |
kojic acid results in increased expression of EP300 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 7:113,108,476...113,178,529
Ensembl chr 7:113,106,247...113,136,088 Ensembl chr 7:113,106,247...113,136,088
|
|
G |
Epha10 |
EPH receptor A10 |
decreases expression |
ISO |
kojic acid results in decreased expression of EPHA10 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 5:137,139,588...137,175,637
Ensembl chr 5:137,140,735...137,174,157
|
|
G |
Epha4 |
Eph receptor A4 |
increases expression |
ISO |
kojic acid results in increased expression of EPHA4 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 9:78,815,460...78,958,139
Ensembl chr 9:78,815,460...78,958,139
|
|
G |
Ephx1 |
epoxide hydrolase 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of EPHX1 mRNA; [Diethylnitrosamine co-treated with kojic acid] results in increased expression of EPHX1 mRNA |
CTD |
PMID:18544905 |
|
NCBI chr13:92,714,315...92,744,105
Ensembl chr13:92,714,315...92,790,235
|
|
G |
Ephx2 |
epoxide hydrolase 2 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of EPHX2 mRNA; [Diethylnitrosamine co-treated with kojic acid] results in increased expression of EPHX2 mRNA |
CTD |
PMID:18544905 |
|
NCBI chr15:40,289,901...40,327,632
Ensembl chr15:40,289,902...40,327,615
|
|
G |
Ercc2 |
ERCC excision repair 2, TFIIH core complex helicase subunit |
multiple interactions |
ISO |
[Diethylnitrosamine co-treated with kojic acid co-treated with Ascorbic Acid] results in increased expression of ERCC2 mRNA |
CTD |
PMID:17917374 |
|
NCBI chr 1:79,033,342...79,047,102
Ensembl chr 1:79,033,326...79,047,102
|
|
G |
Ercc3 |
ERCC excision repair 3, TFIIH core complex helicase subunit |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of ERCC3 mRNA |
CTD |
PMID:18544905 |
|
NCBI chr18:23,883,613...23,914,326
Ensembl chr18:23,883,580...23,914,329
|
|
G |
Ercc4 |
ERCC excision repair 4, endonuclease catalytic subunit |
multiple interactions |
ISO |
[Diethylnitrosamine co-treated with kojic acid co-treated with Ascorbic Acid] results in increased expression of ERCC4 mRNA |
CTD |
PMID:17917374 |
|
NCBI chr10:2,416,259...2,448,364
Ensembl chr10:2,419,038...2,448,369 Ensembl chr10:2,419,038...2,448,369
|
|
G |
Ercc5 |
ERCC excision repair 5, endonuclease |
multiple interactions |
ISO |
[Diethylnitrosamine co-treated with kojic acid co-treated with Ascorbic Acid] results in increased expression of ERCC5 mRNA |
CTD |
PMID:17917374 |
|
NCBI chr 9:46,309,477...46,354,478
Ensembl chr 9:46,309,389...46,354,472
|
|
G |
Esam |
endothelial cell adhesion molecule |
increases expression |
ISO |
kojic acid results in increased expression of ESAM mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 8:37,238,228...37,249,217
Ensembl chr 8:37,238,287...37,249,215
|
|
G |
Esrp1 |
epithelial splicing regulatory protein 1 |
increases expression |
ISO |
kojic acid results in increased expression of ESRP1 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 5:24,427,611...24,482,157
Ensembl chr 5:24,428,717...24,482,062
|
|
G |
Exd1 |
exonuclease 3'-5' domain containing 1 |
decreases expression |
ISO |
kojic acid results in decreased expression of EXD1 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 3:106,507,839...106,535,922
Ensembl chr 3:106,508,076...106,535,922
|
|
G |
Exoc2 |
exocyst complex component 2 |
increases expression |
ISO |
kojic acid results in increased expression of EXOC2 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr17:33,506,289...33,698,246
Ensembl chr17:33,506,338...33,693,289
|
|
G |
F10 |
coagulation factor X |
increases expression |
ISO |
kojic acid results in increased expression of F10 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr16:76,468,834...76,488,141
Ensembl chr16:76,468,838...76,488,141
|
|
G |
Fam241a |
family with sequence similarity 241 member A |
increases expression |
ISO |
kojic acid results in increased expression of FAM241A mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 2:216,344,563...216,375,193
Ensembl chr 2:216,343,822...216,375,242
|
|
G |
Fbn2 |
fibrillin 2 |
increases expression |
ISO |
kojic acid results in increased expression of FBN2 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr18:51,499,670...51,703,976
Ensembl chr18:51,499,737...51,703,976
|
|
G |
Fbxo16 |
F-box protein 16 |
increases expression |
ISO |
kojic acid results in increased expression of FBXO16 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr15:39,492,268...39,541,493
Ensembl chr15:39,492,377...39,541,480
|
|
G |
Ferry3 |
FERRY endosomal RAB5 effector complex subunit 3 |
decreases expression |
ISO |
kojic acid results in decreased expression of FERRY3 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 4:159,772,693...159,809,322
Ensembl chr 4:159,772,786...159,806,382
|
|
G |
Fgf12 |
fibroblast growth factor 12 |
increases expression |
ISO |
kojic acid results in increased expression of FGF12 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr11:71,997,151...72,564,757
Ensembl chr11:71,997,099...72,562,607
|
|
G |
Fgf5 |
fibroblast growth factor 5 |
decreases expression |
ISO |
kojic acid results in decreased expression of FGF5 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr14:11,323,827...11,346,164
Ensembl chr14:11,325,334...11,345,997
|
|
G |
Fgfr3 |
fibroblast growth factor receptor 3 |
decreases expression |
ISO |
kojic acid results in decreased expression of FGFR3 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr14:76,987,242...77,002,671
Ensembl chr14:76,987,993...77,003,341
|
|
G |
Fibcd1 |
fibrinogen C domain containing 1 |
decreases expression |
ISO |
kojic acid results in decreased expression of FIBCD1 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 3:15,092,682...15,126,371
Ensembl chr 3:15,092,681...15,126,399
|
|
G |
Fkbp10 |
FKBP prolyl isomerase 10 |
increases expression |
ISO |
kojic acid results in increased expression of FKBP10 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr10:85,345,434...85,357,998
Ensembl chr10:85,346,126...85,427,330
|
|
G |
Fmo1 |
flavin containing dimethylaniline monoxygenase 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of FMO1 mRNA; [Diethylnitrosamine co-treated with kojic acid] results in increased expression of FMO1 mRNA |
CTD |
PMID:18544905 |
|
NCBI chr13:75,182,184...75,214,439
Ensembl chr13:75,182,176...75,214,647
|
|
G |
Fpgt |
fucose-1-phosphate guanylyltransferase |
decreases expression |
ISO |
kojic acid results in decreased expression of FPGT mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 2:244,099,031...244,119,967
Ensembl chr 2:244,099,076...244,119,899
|
|
G |
Frmpd4 |
FERM and PDZ domain containing 4 |
decreases expression |
ISO |
kojic acid results in decreased expression of FRMPD4 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr X:25,853,849...26,814,642
Ensembl chr X:25,853,934...26,814,637
|
|
G |
Fsaf1 |
40S small subunit processome assembly factor 1 |
decreases expression |
ISO |
kojic acid results in decreased expression of FSAF1 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr19:52,807,932...52,822,259
Ensembl chr19:52,807,934...52,822,267
|
|
G |
Fth1 |
ferritin heavy chain 1 |
increases expression |
ISO |
kojic acid results in increased expression of FTH1 mRNA; kojic acid results in increased expression of FTH1 protein |
CTD |
PMID:23738040 |
|
NCBI chr 1:206,627,142...206,629,430
Ensembl chr 1:206,627,103...206,725,424
|
|
G |
Fzd8 |
frizzled class receptor 8 |
increases expression |
ISO |
kojic acid results in increased expression of FZD8 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr17:57,312,924...57,320,551
Ensembl chr17:57,314,450...57,320,650
|
|
G |
Gadd45b |
growth arrest and DNA-damage-inducible, beta |
multiple interactions |
EXP |
[Ascorbic Acid co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of GADD45B mRNA |
CTD |
PMID:18544905 |
|
NCBI chr 7:8,778,004...8,780,306
Ensembl chr 7:8,778,007...8,780,046
|
|
G |
Galnt1 |
polypeptide N-acetylgalactosaminyltransferase 1 |
decreases expression |
ISO |
kojic acid results in decreased expression of GALNT1 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr18:15,489,015...15,568,849
Ensembl chr18:15,489,020...15,568,245
|
|
G |
Gfod1 |
Gfo/Idh/MocA-like oxidoreductase domain containing 1 |
decreases expression |
ISO |
kojic acid results in decreased expression of GFOD1 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr17:21,400,142...21,504,972
Ensembl chr17:21,399,479...21,499,938
|
|
G |
Gle1 |
GLE1 RNA export mediator |
decreases expression |
ISO |
kojic acid results in decreased expression of GLE1 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 3:13,209,312...13,237,018
Ensembl chr 3:13,209,322...13,237,379
|
|
G |
Gmpr |
guanosine monophosphate reductase |
decreases expression |
ISO |
kojic acid results in decreased expression of GMPR mRNA |
CTD |
PMID:16595896 |
|
NCBI chr17:19,151,820...19,189,626
Ensembl chr17:19,151,815...19,189,621
|
|
G |
Gnb1 |
G protein subunit beta 1 |
increases expression |
ISO |
kojic acid results in increased expression of GNB1 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 5:166,075,508...166,142,223
Ensembl chr 5:166,075,629...166,142,124
|
|
G |
Gpr146 |
G protein-coupled receptor 146 |
decreases expression |
ISO |
kojic acid results in decreased expression of GPR146 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr12:15,251,936...15,267,217
Ensembl chr12:15,251,813...15,267,206
|
|
G |
Gpr26 |
G protein-coupled receptor 26 |
decreases expression |
ISO |
kojic acid results in decreased expression of GPR26 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 1:186,766,001...186,805,435
Ensembl chr 1:186,767,062...186,784,568
|
|
G |
Gpr32 |
G protein-coupled receptor 32 |
increases expression |
ISO |
kojic acid results in increased expression of GPR32 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 1:94,756,863...94,757,895
|
|
G |
Gpr61 |
G protein-coupled receptor 61 |
decreases expression |
ISO |
kojic acid results in decreased expression of GPR61 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 2:195,781,931...195,789,798
Ensembl chr 2:195,782,752...195,789,621
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of GPX1 mRNA; [Diethylnitrosamine co-treated with kojic acid] results in increased expression of GPX1 mRNA |
CTD |
PMID:18544905 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Gsdma |
gasdermin A |
decreases expression |
ISO |
kojic acid results in decreased expression of GSDMA mRNA |
CTD |
PMID:16595896 |
|
NCBI chr10:83,614,336...83,639,543
Ensembl chr10:83,627,051...83,639,543
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
ISO |
[Diethylnitrosamine co-treated with kojic acid co-treated with Ascorbic Acid] results in increased expression of GSR mRNA |
CTD |
PMID:17917374 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Gsta2 |
glutathione S-transferase alpha 2 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of GSTA2 mRNA; [Diethylnitrosamine co-treated with kojic acid] results in increased expression of GSTA2 mRNA |
CTD |
PMID:18544905 |
|
NCBI chr 8:79,184,535...79,196,827
Ensembl chr 8:79,184,322...79,196,798
|
|
G |
Gsta3 |
glutathione S-transferase alpha 3 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of GSTA3 mRNA; [Diethylnitrosamine co-treated with kojic acid] results in increased expression of GSTA3 mRNA |
CTD |
PMID:18544905 |
|
NCBI chr 9:23,658,574...23,684,240
Ensembl chr 9:23,658,574...23,684,240
|
|
G |
Gsta4 |
glutathione S-transferase alpha 4 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with kojic acid] results in increased expression of GSTA4 mRNA |
CTD |
PMID:18544905 |
|
NCBI chr 8:79,066,967...79,084,193
Ensembl chr 8:79,066,934...79,084,182
|
|
G |
Gstm1 |
glutathione S-transferase mu 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of GSTM1 mRNA; [Diethylnitrosamine co-treated with kojic acid] results in increased expression of GSTM1 mRNA |
CTD |
PMID:18544905 |
|
NCBI chr 2:195,649,845...195,655,402
Ensembl chr 2:195,649,845...195,655,411
|
|
G |
Gstm2 |
glutathione S-transferase mu 2 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of GSTM2 mRNA; [Diethylnitrosamine co-treated with kojic acid] results in increased expression of GSTM2 mRNA |
CTD |
PMID:18544905 |
|
NCBI chr 2:195,624,015...195,628,774
Ensembl chr 2:195,544,426...195,628,961
|
|
G |
Gstm5 |
glutathione S-transferase, mu 5 |
multiple interactions |
ISO EXP |
[Diethylnitrosamine co-treated with kojic acid] results in increased expression of GSTM3 mRNA [Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of GSTM3 mRNA; [Diethylnitrosamine co-treated with kojic acid] results in increased expression of GSTM3 mRNA |
CTD |
PMID:17917374 PMID:18544905 |
|
NCBI chr 2:195,531,599...195,534,562
Ensembl chr 2:195,531,495...195,534,553
|
|
G |
Gucy1a2 |
guanylate cyclase 1 soluble subunit alpha 2 |
decreases expression |
ISO |
kojic acid results in decreased expression of GUCY1A2 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 8:500,212...900,201
Ensembl chr 8:500,212...889,203
|
|
G |
H1f1 |
H1.1 linker histone, cluster member |
increases expression |
ISO |
kojic acid results in increased expression of H1-1 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr17:41,366,268...41,367,011
Ensembl chr17:41,366,268...41,367,011
|
|
G |
Hand1 |
heart and neural crest derivatives expressed 1 |
increases expression |
ISO |
kojic acid results in increased expression of HAND1 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr10:42,006,646...42,009,213
Ensembl chr10:42,006,651...42,009,213
|
|
G |
Harbi1 |
harbinger transposase derived 1 |
decreases expression |
ISO |
kojic acid results in decreased expression of HARBI1 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 3:77,681,431...77,689,749
Ensembl chr 3:77,681,431...77,689,724
|
|
G |
Hibch |
3-hydroxyisobutyryl-CoA hydrolase |
decreases expression |
ISO |
kojic acid results in decreased expression of HIBCH mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 9:48,590,097...48,669,896
Ensembl chr 9:48,590,099...48,669,824
|
|
G |
Hint3 |
histidine triad nucleotide binding protein 3 |
increases expression |
ISO |
kojic acid results in increased expression of HINT3 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 1:27,035,936...27,045,799
Ensembl chr 1:27,035,905...27,047,721
|
|
G |
Hip1 |
huntingtin interacting protein 1 |
increases expression |
ISO |
kojic acid results in increased expression of HIP1 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr12:21,133,364...21,267,796
Ensembl chr12:21,133,406...21,267,725
|
|
G |
Hist1h2al1 |
histone cluster 1 H2A family like 1 |
increases expression |
ISO |
kojic acid results in increased expression of H2AC6 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr17:42,707,954...42,708,420
|
|
G |
Hlf |
HLF transcription factor, PAR bZIP family member |
decreases expression |
ISO |
kojic acid results in decreased expression of HLF mRNA |
CTD |
PMID:16595896 |
|
NCBI chr10:75,154,244...75,211,884
Ensembl chr10:75,154,507...75,211,935
|
|
G |
Hmmr |
hyaluronan-mediated motility receptor |
decreases expression |
ISO |
kojic acid results in decreased expression of HMMR mRNA |
CTD |
PMID:16595896 |
|
NCBI chr10:25,132,933...25,163,029
Ensembl chr10:25,132,977...25,163,060
|
|
G |
Hmox2 |
heme oxygenase 2 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of HMOX2 mRNA |
CTD |
PMID:18544905 |
|
NCBI chr10:10,797,076...10,831,178
Ensembl chr10:10,797,055...10,831,148
|
|
G |
Hnrnph2 |
heterogeneous nuclear ribonucleoprotein H2 |
increases expression |
ISO |
kojic acid results in increased expression of HNRNPH2 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr X:97,780,890...97,786,846
Ensembl chr X:97,780,785...97,787,041
|
|
G |
Hps3 |
HPS3, biogenesis of lysosomal organelles complex 2 subunit 1 |
decreases expression |
ISO |
kojic acid results in decreased expression of HPS3 mRNA |
CTD |
PMID:16595896 |
|
NCBI chr 2:102,484,574...102,527,580
Ensembl chr 2:102,484,574...102,526,047
|
|
G |
Hsp90aa1 |
heat shock protein 90 alpha family class A member 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of HSP90AA1 mRNA |
CTD |
PMID:18544905 |
|
NCBI chr 6:129,702,376...129,707,907
Ensembl chr 6:129,702,383...129,707,268
|
|
G |
Hsp90ab1 |
heat shock protein 90 alpha family class B member 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of HSP90AB1 mRNA; [Diethylnitrosamine co-treated with kojic acid] results in increased expression of HSP90AB1 mRNA |
CTD |
PMID:18544905 |
|
NCBI chr 9:15,432,986...15,438,358
Ensembl chr 9:15,433,691...15,438,488
|
|
G |
Hspa1a |
heat shock protein family A (Hsp70) member 1A |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of HSPA1A mRNA; [Diethylnitrosamine co-treated with kojic acid] results in increased expression of HSPA1A mRNA |
CTD |
PMID:18544905 |
|
NCBI chr20:3,870,765...3,873,221
Ensembl chr20:3,856,006...3,873,227
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of HSPA5 mRNA |
CTD |
PMID:18544905 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Hspb1 |
heat shock protein family B (small) member 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of HSPB1 mRNA |
CTD |
PMID:18544905 |
|
NCBI chr12:20,794,014...20,795,675
Ensembl chr12:20,794,028...20,795,743
|
|
G |
Hspd1 |
heat shock protein family D (Hsp60) member 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of HSPD1 mRNA |
CTD |
PMID:18544905 |
|
NCBI chr 9:56,579,195...56,590,011
Ensembl chr 9:56,579,201...56,589,662
|
|
G |
Hspe1 |
heat shock protein family E (Hsp10) member 1 |
multiple interactions |
EXP ISO |
[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of HSPE1 mRNA [Diethylnitrosamine co-treated with kojic acid co-treated with Ascorbic Acid] results in increased expression of HSPE1 mRNA |
CTD |
PMID:17917374 PMID:18544905 |
|
NCBI chr 9:56,589,912...56,593,000
Ensembl chr 9:56,589,789...56,593,089
|
|
G |
Hyou1 |
hypoxia up-regulated 1 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of HYOU1 mRNA |
CTD |
PMID:18544905 |
|
NCBI chr 8:44,706,073...44,718,189
Ensembl chr 8:44,706,263...44,718,186
|
|
G |
Igf2r |
insulin-like growth factor 2 receptor |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with kojic acid co-treated with Diethylnitrosamine] results in decreased expression of IGF2R mRNA |
CTD |
PMID:18544905 |
|
NCBI chr 1:47,979,109...48,067,501
Ensembl chr 1:47,979,109...48,067,501
|
|
G |
Il1a |
interleukin 1 alpha |
multiple interactions |
| |